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Drug development depends on accurately identifying 
molecular targets that both play a causal role in a disease 
and are amenable to pharmacological action by small 
molecule drugs or bio-therapeutics, such as monoclonal 
antibodies.  
 
Errors in drug target specification contribute to the 
extremely high rates of drug development failure.   
 
Integrating knowledge of genes that encode druggable 
targets with those that influence susceptibility to common 
disease has the potential to radically improve the probability 
of drug development success.  
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Part 1: System flaws in drug development 
 
‘The greatest obstacle to discovery is not ignorance – it is 
the illusion of knowledge’ 
 





The patent and drug regulatory systems encourage 
innovation by rewarding risky but potentially transformative 
research and development (R&D).  However, since 96% of 
drug development programmes currently fail1 2, the 
imbalance between risk and reward in the pharmaceutical 
sector has led to a range of undesirable consequences.   
 
Chief among these is the inflationary pressure on drug 
prices. This is imposed by the need to recoup the incurred 
cost of historical failures through any development 
successes, so as to continue to provide shareholders with a 
return on their investment3.  This cost is borne by healthcare 
systems and transferred to citizens via health insurance 
premiums or taxation.   
 
All too frequently, high-profile failures of anticipated 
‘blockbuster’ or ‘niche-buster’4 drugs lead pharmaceutical 
companies to restructure and refocus in-house R&D, leading 
to job losses, site closures, off-shoring, or mergers and 
acquisitions, aimed at containing cost and supporting the 
company share price in the short to mid-term5 6 7 8. Small 
and medium sized companies (SMEs) in the biotech sector, 
alongside increased public funding of academic translational 
research9, absorb some of the early stage R&D risk.  
However, the interest of these organisations may be less in 
the ultimate therapeutic success of a new drug and more in 
its value as an asset-with-prospects.  Value is often added 
by incremental (rather than definitive) preclinical or early 
clinical phase proof-of-concept studies, before the 
compound, know-how and patent for a disease indication is 
then licensed to the next developer in the chain, and so on.  
Under this model, no single organisation has an end-to-end 
capability or responsibility for taking a potential treatment 
from concept to licence.  
 
With high risk and infrequent reward, R&D can become 
misdirected from the innovative to the derivative 10. This is 
because both the patent and regulatory systems are 
vulnerable to some element of gaming.  New compounds 
with identical mechanisms of action (so called ‘me-too 
treatments’), and minor changes in formulation (e.g. the 
separation of the pharmacologically active stereoisomer 
from an already effective racemic mixture, slow-release 
delivery vehicles for existing drugs, and new combinations 
of old drugs) can occasion a new license and, in effect, the 
same level of patent protection as a drug with a truly novel 
mechanism of action.  Sometimes, patients reap real benefit 
from the improved compound or formulation. More often, 
the process is simply a means for companies to extend 
patent life (ever-greening) 11.  
 
However, healthcare providers are now raising the 
therapeutic bar, such that even newly licensed drugs cannot 
be guaranteed to capture a market share sufficient to recoup 
R&D costs, unless they demonstrate a genuine cost-
effective advance over existing therapies12 13. 
 
In response, governments, who are conflicted in their need 
to ensure cost-efficient healthcare on the one hand, but to 
support the pharmaceutical sector as a major employer and 
taxpayer on the other, have explored schemes to reduce 
barriers to market access. Examples include the 
breakthrough designation scheme in the US14, the priority 
medicines scheme (PRIME) in Europe15, and the Early 
Access to Medicines scheme in the UK16. However, the 
success of such initiatives is reliant on truly innovative and 
transformative products emerging efficiently from 
pharmaceutical R&D pipelines, which has not been the 
experience of the last few decades.  
 
As a consequence, the economic sustainability of the current 
model of drug development has been questioned and calls 
made for some form of disruptive solution to improve both 
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scientific and market efficiency, and to fuel innovation17 18 
19. 
 
Reasons for the high drug development failure rate 
 
To understand how drug development efficiency could be 
improved, it is necessary to understand the reasons for 
failure.  Box 1 summarises the process of drug 
development. 
 
Box 1. The process of drug development20 
Developing a drug with a new mechanism of action requires 
fulfilling a series of tasks in sequence:  
1) Selecting a disease for which there is a deficit in existing 
therapies;  
2) Identifying a pathogenic mechanism and potential drug 
target (almost all of which are proteins);  
3) Screening for and optimising a compound (sometimes a 
small molecule or, increasingly, a monoclonal antibody or 
peptide) that specifically modulates the function of the 
target protein, is free of toxicity and has the desired 
pharmacokinetic properties;  
4) Demonstrating target engagement by the compound 
(through the use of biomarkers or surrogate measures of the 
disease process); and,  
5) Demonstrating efficacy against the disease end-point in 
tandem with an adequate safety profile. 
 
Operationally, this is achieved in two stages: preclinical and 
then clinical. Preclinical studies utilise isolated cells, 
organoid cultures, tissue preparations ex vivo, and (if 
available) animal models of human disease. They test the 
hypothesis that the selected target plays a controlling role in 
the disease of interest (proof of concept) and that the 
compound has an adequate safety profile. If preclinical 
studies are encouraging, a critical decision is made to 
progress to clinical evaluation. This is initially through 
healthy volunteer studies for pharmacokinetics, dose finding 
and tolerability (Phase 1); and then exposure of a small 
number of patients often evaluating surrogate measures of 
disease (Phase 2). If these studies appear promising, a larger 
randomised (Phase 3) outcome trial will follow, typically 10 
or more years after programme initiation, following several 
hundred million pounds of investment.   
 
During the lengthy development process, there is relentless 
attrition of programmes and products. Even for compounds 
reaching clinical phase, only around 10% of entrants emerge 
as licensed drugs.1 2 21 The key productivity-limiting 
obstacle turns out to be ‘late-stage failure’ during phase 2 or 
phase 3 randomised trials22. This has major consequences, 
particularly for smaller pharmaceutical companies with a 
thin therapeutic pipeline and limited financial resources to 
absorb such failures.   
 
But why is late-stage failure a recurrent problem? Two 
decades ago, unfavourable pharmacokinetics was the most 
frequent single cause of clinical phase attrition23. By a 
decade later, this problem had largely been resolved such 
that two thirds of late-stage failures of first-in-class 
compounds can now be attributed to a different problem: 
lack of efficacy in the intended disease, despite adequate 
engagement of the target protein and apparently favourable 
signals from preclinical and early phase clinical studies.24 25 
26 27 28. Thus, most late-stage failures now occur because the 
target turns out not to play the causal role in the disease 
that was hypothesised at the outset.  Late-stage failure for 
lack of efficacy therefore exposes a critical problem in drug 
development: matching the correct drug targets to each 
disease.  The established system of drug development has 
been poor at this crucial task because of two key system 
flaws. 
 
First system flaw: preclinical studies are unreliable 
predictors of development success 
 
Preclinical studies in cell culture systems, tissues, isolated 
organs and animal models that are widely used for drug 
target identification (and validation) have a range of 
acknowledged limitations29.  Cells provide an incomplete 
picture of responses in tissues, which are composed of a 
wide range of interacting cell types. In turn, responses in 
whole organs ex vivo may not reflect the response of the 
whole animal. Experiments in animals may be poorly 
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representative of responses in humans because of species 
differences in pathophysiology, while some animal disease 
models may be an artifice of the human disorder30 31 32. 
Concerns are also now being raised that most (perhaps 
>90%)33 of the nominally positive preclinical research 
studies undertaken in academia (perhaps in industry too), 
and which sometimes seed a drug development programme, 
are often not only poorly representative of human 
pathophysiology but are also frequently irreproducible.  
Investigating the causes of irreproducibility is becoming an 
area of funded research34.  Reasons for irreproducibility 
encompass data selection to flatter or overestimate any real 
effect, and flaws in experimental design, including the 
failure to routinely randomise experimental interventions, 
and to blind the assessment of outcome. A pervasive cause 
of irreproducibility occurs from errors of statistical 
inference arising from common misconceptions about P 
values, including confusion between significance and 
hypothesis testing35 36, which contributes to high rates of 
false discovery37. Box 2 expands on the reasons for the high 
false discovery rate in biomedical research.   
 
Box 2. False discovery rate (𝐹𝐷𝑅) in biomedical research 
A frequent misconception in biomedical research is that the 
false discovery rate (𝐹𝐷𝑅) and the Type 1 (false positive) 
error rate (𝛼) are equivalent 37, 38.  The reason this is not the 
case is illustrated by a hypothetical example. Imagine a field 
of study in which experiments are undertaken with robust 
design: all interventions are allocated at random and, in each 
experiment, the estimated treatment effect has informed the 
sample size such that the experimental false positive error 
rate (𝛼) is 0.05 and the Type 2 (false negative) error rate 
(𝛽), is 0.2. The power, (1 −  𝛽), which can be 
conceptualised as the detection rate for a real effect, is 
therefore 0.8.   We introduce a third parameter (𝛾), the 
proportion of true relationships out of all those tested in the 
field. In the current illustration, we assume 𝛾 = 0.1.  Table 
1a illustrates that, despite the robust experimental design, 
these parameters dictate that 36% (not 5%) of nominally 
positive experimental outcomes are false discoveries. In 
general, 𝐹𝐷𝑅 is related to 𝛼, 𝛽 and 𝛾 as follows: 
 
𝐹𝐷𝑅 =  
 𝛼(1−𝛾) 
(1−𝛽) 𝛾 + 𝛼 (1−𝛾)
    
(Equation 1)  
              
Table 1b and Table 2 demonstrate how 𝐹𝐷𝑅 varies at 
different values of 𝛼, 𝛽 and 𝛾.  Reducing 𝛼 has the effect of 
reducing 𝐹𝐷𝑅. Increasing 𝛽 (equivalent to reducing power, 
e.g. from 0.8 to 0.2, which is close to the mean power 
recently found in a survey of preclinical studies in the field 
of neuroscience)39 increases 𝐹𝐷𝑅 (from 36% to 69% in this 
example, so that false discoveries would then outnumber 
true discoveries by about 2:1). 𝐹𝐷𝑅 increases as the 
proportion of true relationships (𝛾) decreases. In addition, it 
is not widely appreciated that real effects, even when 
present can be overestimated by small studies, because a 
positive finding must be extreme for it to exceed the usual 
experimental significance threshold (a similar notion to 
small study bias in clinical trials, and the winner’s curse40).  
 
Many previous discussions of the extent of the 𝐹𝐷𝑅 
problem have been somewhat abstract in nature.  But is it 
possible to estimate real-world 𝐹𝐷𝑅, and, if so, to compute 
the impact on drug development success rates?   
 
By setting some simplifying assumptions and 
approximating certain parameters, we now estimate 𝐹𝐷𝑅 
for preclinical studies that usually provide a start point for 
drug development.   
 
Understanding disease aetiology can frequently be distilled 
to understanding which of the proteins encoded in the 
genome plays a controlling or causal role in each disease 
process. Drug targets are also almost exclusively proteins. 
We therefore introduce the following: 
 
Assumption 1: Each gene encodes a unique protein with a 
single function 
Assumption 2: A given protein can influence the risk of 
more than one disease  
Assumption 3: The probability of a protein influencing the 
pathogenesis of one disease is independent of the 
probability that it influences any other  
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
5 
 
We recognise that these assumptions, as well as others we 
will introduce in due course, represent very substantial 
oversimplifications, and many exceptions can be identified 
from current drugs and diseases. However, they can also 
help to estimate certain ‘base-case’ probabilities.  Later in 
this article we dissect these assumptions, as well as others 
we introduce later, and explore the impact of any 
modifications on the base-case probabilities.  
 
The key parameters needed for the estimation of 𝐹𝐷𝑅 in 
biomedical research are the number of human diseases of 
interest; the number of protein coding genes; and the 
average number of proteins that are likely to play a causal 
role in any given disease.  
 
Taking the complexities and inaccuracies of disease 
definition into account (see Box 3 and Table 3 for details), 
we assume, as a start point, that the number of complex 
(multifactorial) diseases is close to 10,000, and that the 
number of human protein coding genes41 is around 
20,000 (Figure 1). Box 4 provides a historical overview of 
the route to establishing this estimate.  
 
Box 3.  Estimating the number of human disease entities 
Estimating the exact number of human diseases is a 
surprisingly challenging task. Clinical priorities have led to 
definitions of disease that rely on characteristic clusters of 
symptoms and signs supported to a varying degree by 
biophysical, laboratory, radiological or histological tests that 
detect abnormalities of structure or function.  Defining 
disease on the basis of manifestations rather than cause 
means that diagnoses may be remote from the molecular 
mechanisms leading to disease, many of which remain 
unknown.  In this paper, we set aside rare monogenic 
conditions, focusing instead on common (multifactorial) 
human diseases of potential therapeutic interest that have 
both a genetic and environmental contribution. A list of 
medical coding schemes covering such diseases, from 
clinical terminologies to disease classification systems, is 
shown in Table 3. Standard vocabularies of medical terms 
such as SNOMED CT (Systematised Nomenclature of 
Medicine - Clinical Terms) which includes Read Clinical 
Terms Version 3 (CTV3), which are used in electronic 
health records, capture clinically relevant data related to 
individuals and their care. The difficulty with using these 
vocabularies to enumerate diseases is that multiple codes 
can refer to a single disease, both because of duplicate terms 
(largely rectified in SNOMED CT) and the hierarchical 
nature of these vocabularies. In addition, disease diagnoses 
comprise only a proportion of the descriptive terms, with 
many covering symptoms, procedures, treatments, drugs 
and healthcare administration. The International 
Classification of Diseases (ICD) is widely regarded as the 
authoritative classification system for causes of death and 
illnesses. Its use in recent revisions has been broadened to 
medical records indexing and reimbursement. 
Approximately 4,000 of over 12,000 classes in the tenth 
revision, ICD-10, refer to health administration and external 
causes of morbidity and mortality and their consequences. 
Of the more than 8,000 remaining classes, (fewer than 500 
of which are specific for rare diseases)42 43, overlaps occur 
within the hierarchical coding structure, such that a 
particular disease may be described by several codes. The 
same is true of disease and phenotype ontologies. 
Categorisation schemes such as the Clinical Classification 
Software developed by the US Agency for Healthcare 
Research and Quality (AHRQ), the Expanded Diagnostic 
Clusters (EDC) developed at Johns Hopkins University and 
the PheWAS Catalog designed at Vanderbilt University, 
collapse ICD codes into a smaller number of clinically 
meaningful categories that can be useful for presenting 
descriptive statistics.   
 
Box 4. Estimating the number of protein coding genes in the 
human genome 
As summarised by Pertea and Salzberg44, estimates of the 
number of human protein-coding genes have been revised 
progressively downward since the early 1960s.  Very early 
estimates, predating the first draft of the human genome by 
around 40 years, were based on extrapolation from 
emerging information on the amino acid sequences of 
proteins45, or theoretical considerations46.  When the human 
genome project was at its planning stage, the number of 
human genes was projected to stand at 50-100,000 (National 
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Institutes of Health/Department of Energy report on the 
Human Genome Project).  However, when the initial results 
emerged, the estimate was revised to around 25-30,000 
genes47.  With more exhaustive sequencing of the genome 
and its transcripts, more detailed annotation of sequence, 
comparative analysis of proteomic and sequence data, and 
the construction of a tissue based map of the human 
proteome48, the consensus estimate of the number of protein 
coding genes has fallen yet again49.   Summary statistics on 
the human genome are now regularly updated by the 
GENCODE project.   The resource has catalogued a 
consensus value for the number of human genes since 2009, 
at which time 22,250 protein-coding genes were listed.  In 
the latest data freeze (March 2016, Version 25), the number 
of genes listed is 19,950.  
 
To estimate the average number of protein-coding genes 
that play a causal role in any given disease, we draw on 
experience from previous genome wide association studies 
(GWAS; see Box 5).  This is the only routinely used study 
design that estimates the influence of every gene (and 
protein) on a disease systematically.  The ability to detect 
disease-causing genes differs from one GWAS to the next, 
depending both on the underlying genetic effect in the 
disease of interest and the available sample size. We 
therefore confine our consideration to those GWAS and 
meta-analysis of GWAS (meta-GWAS) with the very 
largest sample sizes.  Examples of such meta-GWAS 
include inflammatory bowel disease (60,000 individuals 
studied; 99 loci identified)50, type 2 diabetes (150,000 
individuals; 150 loci)51, and coronary heart disease (200,000 
individuals; 46 loci)52.  Thus, each of these meta-GWAS has 
identified in the order of 100 susceptibility loci per disease. 
The number of disease-associated loci may not equate 
precisely to the number of causal genes per disease, and it 
may also be anticipated that yet larger sample sizes will 
yield yet more loci, because much of the heritability of 
common disorders remains unexplained53. There is also a 
school of thought that all genes (and proteins) play some 
role in all diseases – the infinitesimal54 or omnigenic55 
model – which we discuss in more detail later. However, 
with these caveats, let us assume, initially, that there are 100 
causal genes per disease on average. 
 
We now define the following: 
 
{𝐺} is the set of protein − coding genes  
{𝐷} is the set of common human diseases  
{𝐺𝐷} is the set of all possible gene − disease pairs   
{𝐶} is the set of causal genes for a given disease 
{𝐶𝐷} is the set of all causal gene − disease pairs  
 
 𝑁𝐺 =  Total number of protein − coding genes =  20,000  
𝑁𝐷  =  Total number of complex human diseases =  10,000  
𝑁𝐺𝐷   =  Total number of possible gene − disease pairs
= 10,000 ×  20,000 =  200 x 106 
𝐶 = the number of causal genes in a given disease 
𝐶̅ =  the average number of causal genes per disease =  100  
 𝑁𝐶𝐷   =  Total number of causal gene − disease pairs  
=  100 ×  10,000 =  1 x 106 
 
Based on assumptions 1-3, the probability (𝑃𝑐) that any 
gene- (or, equivalently, any protein)-disease pairing selected 
at random from the set of all possible gene-disease pairs 
{𝐺𝐷} also belongs to the set of causal gene-disease pairs 




















This can also be written as: 
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 if 𝐶̅  = 1000, but 𝑃𝐶  falls to 
1
2000
 if 𝐶̅ = 10.  
 
As follows from Equation 3, 𝑃𝑐  is independent of the 
number of diseases under consideration, as long as 𝐶̅ is 
constant. As an illustration, focusing on 5000 diseases 
(rather than 10,000) would shrink the sample space by half 
to 5000 ×  20,000 (= 100 ×  106) gene (protein)-disease-
pairings, but would also reduce the number of causal gene 
(protein)-disease pairs in the sample space by the same 
proportion, from 1 ×  106 to 500,000.  
 
Importantly, 𝑃𝐶  can also be interpreted as the proportion of 
true hypotheses for tests of causality amongst all possible 
gene-disease pairings, and can hence also be represented as 
𝛾𝐶 (see Box 2). In this case, 𝛾𝐶 refers to the probability of a 
true causal gene-disease pairing occurring within the sample 
space {𝐺𝐷}.  Therefore: 
 
𝑃𝐶  =  𝛾𝐶   
(Equation 4) 
4 
Let us now consider preclinical experiments designed such 
that 𝛼 = 0.05, and a detection rate (power) for causal 
pairings (1 −  𝛽)  = 0.8.   
 
𝐹𝐷𝑅 =  
 𝛼(1−𝛾) 
(1−𝛽) 𝛾 + 𝛼 (1−𝛾)
    
(Equation 1) 
 
If 𝐶̅ = 100 and 𝛾𝐶  = 0.005:  
 
𝐹𝐷𝑅 =  92.6%  
 
This 𝐹𝐷𝑅 value for biomedical research is very close to that 
estimated previously by Ioannidis33.  
 
However, scientists, it might be argued, do not select 
protein-disease pairings at random: they work on particular 
diseases and proteins that have been seemingly confidently 
paired on the basis of previous research.  Scientists are also 
not generally interested in identifying a protein that is causal 
for any disease, but rather in identifying proteins 
contributing to the pathogenesis of a particular disease of 
interest, a point to which we return in a later section.  But if, 
as Ioannidis and others have argued, there is strong 
empirical evidence from many research fields of extremely 
high rates of false discovery, leading to pervasive 
unreliability of the evidence base, then seemingly informed 
hypotheses may turn out to be spurious56. In Bayesian 
terms, the prior probability of correctly pairing a gene (or 
protein) with a disease may be close to that of the 
background probability of a success in a random pick from 
the sample space. The proportion of false discoveries in the 
medical literature could be inflated further because of the 
greater likelihood of positive than negative findings being 
submitted and accepted for publication57.   
 
For now, in summary, preclinical research is poorly 
predictive of drug development success partly because of 
the poor external validity of cell, tissue and animal models, 
partly because of flaws in experimental design and 
significance chasing and publication bias, but perhaps 
mainly because of the pervasive 𝐹𝐷𝑅 problem.  This occurs 
because: 
 
a) Preclinical studies are often too small to detect true 
positive associations because the actual power 
(1 −  𝛽) is lower than that pre-specified at the 
study design stage because of over-optimistic 
estimates of effect sizes: when real associations are 
detected, the effect sizes will be overestimated.  
b) The usual experimental false positive rate (𝛼) of 
0.05 leads to an excess of false discoveries 
because;  
c) Causally-relevant gene (or protein)-disease 
pairings (true disease hypotheses) in most areas of 
research are greatly outnumbered by the number of 
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
8 
 
non-causal ones, that is the value of 𝛾𝐶 tends to be 
small, often far below 0.1.   
 
It is easy to envisage how these conditions could lead to 
drug development programmes being initiated on the basis 
of misleading preclinical research, progressing into the 
clinical phase of development only to stumble expensively 
at phase 2 or 3.   
 
Expensive late-stage failure would appear to be an 
consequence of the high 𝐹𝐷𝑅 in preclinical target validation 
studies. But is it avoidable? 
 
 Lessons can be learnt from the field of common disease 
genetics, which overcame the high 𝐹𝐷𝑅 problem in the era 
of candidate gene association studies. Resolution was 
achieved through a complete re-examination of the way in 
which research in that field was conducted.  As a 
consequence, genetic association studies now yield some of 
the most reproducible findings in any field of biomedicine, 
detecting loci throughout the genome influencing a wide 
range of diseases and biomarkers58. The steps taken to 
rescue common disease genetics from the epidemic of false 
discoveries in the ‘candidate gene era’ are summarized in 
Box 559.  
 
Box 5. Resolution of the high false discovery rate problem 
in the field of common disease genetics  
Three major factors contributed to the resolution of the high 
𝐹𝐷𝑅 problem in the field of common disease genetics in the 
candidate gene era. These were: 
a) The development of fixed content genotyping arrays that, 
to a first approximation, could interrogate all genes in a 
genome, not just a subset of them, triggering the move from 
candidate gene to whole-genome (genome-wide) association 
studies (GWAS);  
b) Recognition that a much more stringent -value 
threshold would be needed in such studies to minimize false 
discoveries, as can be observed from Table 2, where 
changing 𝛼 from 0.05 to 5 ×  10−8 (the now widely used 
genome wide Type I error rate) reverses 𝑇𝐷𝑅 and 𝐹𝐷𝑅 
c) Understanding that larger sample sizes than had been 
usual up to that time would be needed to retain power in the 
context of the much stricter -value threshold.  As a 
consequence, clinicians and scientists began to assemble 
large collections of patients with diseases of interest (and 
controls) and, by necessity, to work together in consortia to 
achieve datasets of the necessary size, pooling information 
from individual studies in a statistically robust way using 
meta-analysis, a technique which, by then, had already 
become well-established in the clinical trial setting.  A 
GWAS incorporating data from over 200,000 individuals 
by meta-analysis would now be viewed as unexceptional.  
The findings from GWAS are curated by a number of 
repositories 60 61 including the NHGRI-EBI GWAS catalog 
at https://www.ebi.ac.uk/gwas/.  
 
Yet, while the problem of high false discovery rates has led 
to a root and branch change in the field of complex disease 
genetics, a similar transformation is yet to take place in 
preclinical laboratory science that precedes most drug 
development.  The 𝛼-value of 0.05 remains almost 
universal in preclinical studies.  The power (1 − 𝛽) 
continues to be lower than asserted because of the over-
estimation of effect sizes and consequent under-estimation 
of necessary sample sizes. Moreover, the prior probability 
of a hypothesis being true, (𝛾), may not be much greater 
than for a randomly selected hypothesis, given that many of 
the research findings purported to support the tested 
hypothesis may themselves be false discoveries. 
 
Second system flaw: the definitive target validation 
experiment is delayed to the end of drug development 
pipeline 
 
The phase 3 randomised controlled trial (RCT) is often 
regarded simply as a test of the efficacy and safety of a new 
compound for a particular disease indication.  However, 
when the compound evaluated is the first in its class, the 
RCT is also the first human test of the causal relevance of a 
previously untested drug target in a particular disease. This 
exposes the second major system flaw in the development 
of drugs with a novel mechanism of action: the most 
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important target identification and validation experiment is 
the concluding not the initiating step.  Risk therefore 
accumulates rather than diminishes as a drug development 
programme progresses towards the RCT, accounting for the 
high actual and opportunity cost of late-stage failure.  
A theoretical solution to this problem would be to obtain 
large-scale randomised human evidence on a target and 
disease state earlier in a drug development programme, 
without recourse to developing a medicinal compound to 
obtain the necessary evidence.  Though this might seem 
unattainable at first glance, human genomics again provides 
a solution.  Population genetic association studies can be 
viewed as 'natural randomized trials’ without drugs 62 63 64 65. 
This is because germ line genetic variants such as single 
nucleotide polymorphisms (SNPs), which associate with 
differences in expression or activity of an encoded protein, 
assort at random according to Mendel’s Law, in an 
analogous way to drug treatment allocation in a randomised 
clinical trial.   
 
In comparisons of genetic associations in populations with 
drug treatment effects in clinical trials, using a set of 
biomarkers and disease outcomes common to both study 
types, SNPs in a gene encoding a potential drug target have 
been observed to anticipate the mechanism-based effect of 
pharmacological action on the same protein. The approach 
is sometimes referred to as Mendelian randomisation for 
drug target validation (see Appendix 1, Ref 1),  since it was 
inspired by, and represents a special case of the Mendelian 
randomisation paradigm, developed initially to help 
determine the causal relevance of environmental exposures 
or disease related biomarkers66.  Mendelian randomisation 
for drug target validation is disease agnostic, though it may 
be unsuited to aspects of cancer drug development, where 
somatic rather than germ line mutations perturb the targets 
of interest, or to the development of anti-infective drugs, in 
cases where the therapeutic drug target is in the pathogen 
rather than the human host.  
 
Importantly, genotyping arrays containing many thousands 
of SNPs across the genome, including those in genes 
encoding potential drug targets, provide the opportunity to 
interrogate systematically the influence of genetically 
mediated target perturbation on hundreds (eventually 
perhaps thousands) of biomarkers and disease outcomes in 
parallel, in a manner analogous to high-throughput 
compound screening (HTS) against a target.  In this way, a 
genome-wide extension of the Mendelian randomisation 
paradigm could be used for drug target identification. 
 
Genomic studies for disease-specific target identification 
 
There are sound reasons for thinking that genomic studies to 
specify drug targets for a human disease is likely to be a 
more reliable approach than the standard hypothesis-driven, 
non-genomic preclinical research in cells, tissues and animal 
models described previously. This is because: 
 
a) The evidence obtained in GWAS comes from intact 
humans, the species of interest, not isolated cells, 
tissues studied ex vivo, or animal models  
b) GWAS are some of the most statistically robust study 
designs in any field of biomedicine by virtue of their 
low false discovery rates, large sample sizes and the 
routine replication of positive findings 
c) Genetic associations are protected from certain biases 
that affect other human observational study designs by 
virtue of the natural randomisation of genetic variants, 
which mimics treatment allocation in an RCT. 
d) With appropriate coverage of the set of genes encoding 
human drug targets, and an adequate sample size, 
GWAS can be conducted for most (if not all) human 
drug targets simultaneously 
 
Indeed, the same arguments apply to studies in which whole 
exome or whole genome sequencing (rather than 
genotyping) is used as the primary means of acquiring 
information on naturally occurring genetic variation and its 
association with disease.  
 
Evidence is already emerging that such genetic association 
studies can help systematically match the correct drug 
targets to the correct disease. This comes partly from the 
like-with-like comparisons of the effects of licensed drugs 
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on biomarkers and disease outcomes in clinical trials with 
the association of variants in the gene encoding 
corresponding drug target in population studies, examples of 
which, now span several diseases (Appendix 1). It also 
comes from the apparently sporadic ‘rediscovery’ by 
GWAS of drug targets already exploited for the treatment of 
the corresponding disease, as well as rediscoveries of the 
known mechanism-based adverse effects of several drug 
classes.  We provide examples of this in Table 4 and a 
linked paper67.   
 
But are such rediscoveries fortunate coincidences or 
predictable occurrences that can be harnessed for the 
purposes of drug development? 
 
To address this question, we formalise some further 
assumptions. Again, we discuss their validity in a later 
section. 
 
Assumption 4: Drug treatments for human disease target 
proteins encoded in the germ linea 
Assumption 5: DNA sequence variants in and around a 
gene encoding a drug target, that alter expression or activity 
of the encoded protein (cis-acting variants) are ubiquitous in 
the genome 
Assumption 6: The association of cis-acting variants with 
biomarkers and disease end-points in a population genetic 
study accurately predict the effects of pharmacological 
modification of the encoded target in a clinical trial  
Assumption 7: Genotyping arrays used in GWAS provide 
comprehensive, appropriately powered coverage of the 
genome, and associations discovered at any one gene are 
independent of those detected at any other 
 
Among those diseases that have at least one licensed drug 
treatment, the total number of targets will vary.  For 
example, nine drug classes (corresponding to nine different 
drug targets) contain compounds currently licensed for the 
treatment of type 2 diabetes (insulin, metformin, 
                                                        
a We exclude drug targets encoded by the abnormal genome of cancer cells 
as well as antimicrobials, which typically target proteins encoded in the 
genomes of pathogens. For further discussion, see Part 4 
sulphonylureas, meglitinides, glitazones, DPP IV inhibitors, 
GLP-1 receptor agonists, SGLT-2 inhibitors and acarbose), 
but only two therapeutic classes (cholinesterase inhibitors 
and NMDA-receptor antagonists) contain compounds 
licensed for treatment of dementia.  We can safely assume, 
from the efficacy of these drugs, that their targets (along 
with others, yet to be identified) play a causal role in those 
diseases.  
 
Consider a hypothetical disease (𝑑1) for which there are 𝑛1 
independent genes encoding targets of drugs that have 
already been licensed on the basis of proven efficacy in the 
condition. We denote these as genes 𝑔1, 𝑔2 … 𝑔𝑛.  Let us 
assume that a GWAS in disease 𝑑1 utilises a genotyping 
array with adequate coverage of all 𝑛1 licensed drug target 
genes, and that there is a probability ((1 − 𝛽1), (1 −  𝛽2) … 
(1-𝛽𝑛1) of detecting the genetic association at each of these 
loci. Thus (1 − 𝛽𝑖) is the power (or the detection rate) for a 
real effect of gene 𝑔𝑖  in disease 𝑑1. 
 
We consider testing for a genetic association at the locus 
encoding each drug target in each hypothetical GWAS of 𝑑1 
to be an independent trial (Assumption 7), where success 
equates to detection of an association at the locus and failure 
to overlooking the association. Consider a situation in which 
there are 3 licensed drug targets in disease 𝑑1 that are 
available for rediscovery, and that power to detect true 
associations is the same at all 3 target loci (i.e. (1 − 𝛽1) =
(1 −  𝛽2)  =  (1 − 𝛽3) = (1 −  𝛽)). The probability of 
missing such a target, is the false negative rate 𝛽.  A GWAS 
in 𝑑1 might detect 0, 1, 2 or all 3 of the known drug targets, 
and the probability that each of these situations occurs is 
given by the binomial distribution: 
 
𝑃 (𝑥) = (
𝑛1
𝑥
) (1 − 𝛽)𝑥𝛽𝑛1−𝑥   
  
𝑃 (𝑥) =  the probability of detecting 𝑥 licensed drug targets  
𝑛1 = the number of licensed drug targets in disease 𝑑1 
𝑛1 − 𝑥 =  the number of undetected  licensed drug targets  
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𝛽 = Type II (false negative) error rate at each genetic locus 
 
If 𝑛1 = 3, and 𝛽 = 0.2, the probability (𝑃) that a GWAS in 
disease 𝑑1: 
 Detects none of the three licensed drug target 
genes, 𝑃(𝑥 = 0) =  𝛽3 =  0.008 
 Detects only one of the three licensed drug target 
genes but misses the remaining two, 𝑃(𝑥 = 1) = 
3𝛽2 (1 − 𝛽)  =  0.096 
 Detects only two of the three licensed drug target 
genes but misses the other, 𝑃(𝑥 = 2) =  3𝛽 (1 −
𝛽) 2  =  0.384 
 Detects all three licensed drug target genes, 
𝑃(𝑥 = 3) =  (1 − 𝛽) 3  =  0.512 
 Detects at least one of the three licensed drug 
target genes, 𝑃(𝑥 > 0) =  1 – 𝛽3   =  1 −
 0.008 =  0.992 
 
In general, the expected (average) number of licensed drug 
target rediscoveries (𝐸𝑑) detected in a GWAS of a disease 
𝑑 with 𝑛𝑑 licensed drug targets will be:   
 
𝐸𝑑  =  (1 − 𝛽1,𝑑)  + (1 − 𝛽2,𝑑)  + (1 − 𝛽3,𝑑)  + ⋯ + (1-
𝛽𝑛𝑑,𝑑) 
 
If power at all loci is (1 − 𝛽): 
 
𝐸𝑑  =  𝑛𝑑 (1 − 𝛽) 
 
The variance (𝑉𝑑) is given by: 
 
𝑉𝑑  =  𝑛𝑑 𝛽  (1 −  𝛽) 
 
For example, for a GWAS conducted in disease 𝑑 with (1 −
𝛽)  =  0.8 at all three loci encoding the targets of licensed 
drugs: 
 
 𝐸𝑑 =  3 ×  0.8 =  2.4 
 
The variance (𝑉𝑑) =  3 ×  0.8 ×  0.2 =  0.48   
 
The standard deviation (𝑆𝐷𝑑)  = √𝑉𝑑 =  0.7 
 
In the worked example, we would therefore expect 
2.4 (𝑆𝐷 =  0.7) of the 3 possible licensed drug targets to be 
rediscovered, on average. 
 
Suppose we do one GWAS for each of 𝐾 different diseases 
(𝑑1, 𝑑2 … 𝑑𝐾) where, for each disease, the number of 
licensed targets available for rediscovery is (𝑛1, 𝑛2, … 𝑛𝐾). 
If we assume that the power to detect an association at gene 
i encoding the target of  licensed drug is the same for all 
drug targets in all GWAS j, regardless of disease  (i.e. (1 −
𝛽𝑖,𝑗)  =  (1 − 𝛽) for all 𝑖 and 𝑗), then the expected number 
of true drug target-indication rediscoveries (𝐸𝑇) across the 
𝐾 GWAS would be the sum of the expected rediscoveries in 
each GWAS. Therefore:  
 
𝐸𝑇   =  𝐸1  +  𝐸2  +  … + 𝐸𝐾      
 
𝐸𝑇    =  (1 −  𝛽)𝑛1  +  (1 −  𝛽)𝑛2  +  … +  (1 −  𝛽)𝑛𝐾   
 








𝑁𝐾 =  (𝑛1  +  𝑛2  +  … + 𝑛𝐾)= the total number of 
licensed drug targets for 𝐾 diseases 
 
Dividing and multiplying the above equation by 𝐾, we 
obtain: 
 
𝐸𝑇 =  𝐾(1 −  𝛽)𝑁𝐾/𝐾   
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?̅?  =  𝑁𝐾/𝐾= the average number of targets of licensed 
drugs per disease  
 
The standard deviation (𝑆𝐷𝑇) is given by: 
 
𝑆𝐷𝑇 =  √𝛽(1 − 𝛽) ?̅? 𝐾  
 
Suppose a GWAS was done for each of 200 different 
diseases, each with power (1 − 𝛽)  =  0.8 to detect each 
true licensed target, and ?̅? = 3 (i.e. an average of 3 targets 
per disease and 𝑁𝐾 = ?̅?𝐾 = 600 potentially re-discoverable 
target-disease combinations in total). 
 
The total number of licensed drug target rediscoveries from 
the combined dataset would be expected to be: 
 
𝐸𝑇   =  (1 −  𝛽)𝑁𝐾 =  480   
 
𝑆𝐷𝑇 =  √0.2 × 0.8 ×  600 = 9.8  
 
Values of 𝐸𝑇  for a range of plausible values of 𝛽 and ?̅?, 
given 𝐾 = 200 are provided in Table S1 
 
It seems reasonable to ask if the number of licensed drug 
target rediscoveries already made by GWAS is close to that 
expected from these arguments. However, the answer is not 
straightforward.  It requires enumerating the number of 
GWAS that have already been done for conditions that 
correspond to either a treatment indication or a mechanism 
based adverse effect for at least one licensed drug target, 
and counting the total number of licensed drug targets 
represented across all these conditions (since some diseases 
may be connected with multiple licensed drug targets). 
These efforts are hampered by different disease 
terminologies being used when cataloguing GWAS, drug 
indications and adverse effects.  There is also a requirement 
to make strong assumptions about the average power of 
eligible GWAS to detect a true association at a gene 
encoding a licensed drug target.  
 
However, the question can be inverted: given the observed 
number of rediscoveries, what was the average power of 
GWAS to rediscover loci encoding licensed drug targets for 
the same indication or through a known mechanism-based 
adverse effect?  We previously reported that GWAS to 2015 
had encompassed 315 unique MeSH disease terms and led 
to the ‘rediscovery’ of 74 of the 670 or so known licensed 
drug targets, either through treatment indication, or 
mechanism-based adverse effect associations67.  
 
To estimate average power, we use: 
 
𝐸𝑇  =  𝐾(1 −  𝛽) ?̅?  
 





(1 −  𝛽) =   
74
?̅?  × 315
 
 













If ?̅?  = 1, (1 − 𝛽) = 0.23 
If ?̅?  < 1, (1 − 𝛽) > 0.23 (as would be the case if some 
GWAS concerned diseases with no licensed drug target 
available for rediscovery) 
If ?̅?  > 1, (1 − 𝛽) < 0.23 
 
Despite the modest estimated average power, the discovery 
by GWAS of around 70 of the 600 or so known licensed 
targets (see Box 6), suggests the approach shows promise as 
a means of identifying target-disease indication pairings 
more systematically in the future, particularly if power were 
to be enhanced. We return to this point in a later section. 
 
Estimating the yield of all druggable targets by GWAS 
 
In the previous section, we discussed the rediscovery of 
known licensed drug targets by GWAS.  In this section, we 
discuss the potential for GWAS to specify new drug targets 
for common diseases prospectively.  
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To estimate the total number of drug target - disease 
indication discoveries that might be possible in adequately 
powered GWAS with comprehensive coverage of the 
genome, we return to the concept of a sample space 
demarcated by 20,000 human genes and 10,000 common 
diseases.  
 
Since only a portion of the genome encodes proteins that are 
readily accessible to small molecule drugs, monoclonal 
antibodies or peptides that currently comprise the major 
chemical categories of medicines, we now define the 
following:   
 
{T}  =  the set of genes encoding druggable targets (the 
druggable genome – See Box 6 for definition) 
 
𝑁𝑇 =  Total number of genes encoding druggable targets =
 4000 (see Box 6) 
 
Box 6. The druggable genome 
In 2002, at a time when the human genome was thought to 
contain ~30,000 protein coding genes, Hopkins and Groom 
estimated that 120 targets had already been exploited by 
licensed drugs but that ~3000 genes in total encoded 
proteins potentially accessible to small molecule agents, 
coining the term ‘the druggable genome 68.   Subsequent 
estimates of the druggable genome have included between 
2000 and 10,000 genes depending on the data set used and 
assumptions made69 70.  Our recent work in developing a 
genotyping array with marker coverage of genes encoding 
actual or potential drug targets, led to a revised estimate that 
approximately 4000 human genes (or about one fifth of the 
protein-coding genome; see Box 4) encode druggable 
proteins 67.  We use this estimate in the calculations that 
follow. Notably more than half of the known small molecule 
drug targets belong to four key gene families: class I G-
protein coupled receptors (GPCRs), nuclear receptors, and 
ligand- or voltage gated ion channels, while targets for 
monoclonal antibodies or peptide therapeutics are cell 
membrane-bound or secreted and circulating proteins71.  
Rask-Anderson et al72 note around 555 targets are already 
exploited by currently licensed drugs (around 12% of the 
druggable genome) with a further 475 unique targets being 
the subject of investigation in clinical trials. More recently, 
Santos et al. estimated that FDA approved drugs for human 
diseases target 667 proteins encoded by the human 
genome71.  Therefore, in combination, about a quarter of the 
druggable genome (one-twentieth of the whole genome), 
has already been drugged by licensed therapies or those in 
clinical phase development.  Note again that antimicrobial 
treatments that interfere with targets in a pathogen rather 
than human host, and cancer treatment targets encoded by 
an abnormal cancer cell genome, distinct from the germ 
line, are excluded from these estimates.  
 
With 𝑁𝐺 =  20,000, and 𝐶̅ = 100, we showed the 
probability 𝑃𝐶  of selecting a causal protein-disease pairing 
from the sample space at random (Equation 3) is given by: 
 











The probability (𝑃𝑇) of selecting a druggable gene 
(protein)-disease pairing at random from the sample space is 
independent of the number of diseases, and is given by: 
 













                                                                                                                   
To estimate the probability 𝑃𝐶𝑇  of selecting a disease-
causing, druggable protein-disease pairing at random from 
the sample space we introduce a further assumption. 
 
Assumption 8: The probability that a protein affects disease 
pathogenesis and the probability the protein can be targeted 




𝑃𝐶𝑇 =  𝑃𝑐 ×  𝑃𝑇     
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𝑃𝐶𝑇 =  
1
200









   
(see Figure 2).  
 
Corresponding probabilities and counts for scenarios in 
which 𝐶̅ = 100, and 𝐶̅ = 1000 are shown in Figure S1 and 
S2 and Table S2. Note that these probabilities are 
independent of 𝑁𝐷, the number of common diseases.  
 
Following the arguments presented previously (see 
Equation 4), 𝑃𝐶𝑇  can also be interpreted as 𝛾𝐶𝑇, the true 
proportion of causal, druggable gene-disease pairs from the 
sample set of all gene-disease pairings.  
 
These probabilities are of general interest, but the 
probability of more direct interest is that of identifying a 
druggable, disease-causing gene having already specified 
the disease of therapeutic interest.  
 
Since we assume the probability of a protein influencing the 
pathogenesis of one disease is independent of the 
probability that it influences any other (Assumption 3), the 
values for 𝑃𝐶 , 𝑃𝑇 and 𝑃𝐶𝑇  are the same for each individual 
disease as they are for the complete sample set.  
 






















These estimates can now be used to re-assort all genes in the 
genome for a given disease from a therapeutic perspective 
(Figure 3).   
 
For example, in the hypothetical disease (𝑑1), where 𝐶 =
100, the expected number of causal and druggable genes is 
given by: 
 






) ×  20,000 =   20 
 
Eighty of the 100 causal genes would therefore be 
categorized as non-druggable.  Of the remaining 19,900 
non-causal genes, one fifth (3980) would be expected to be 
druggable but not causal in disease 𝑑1  (though of course 
they might be causal and of therapeutic interest in a 
different disease).  The remaining 15,920 genes would be 
classified as neither causal for 𝑑1, nor druggable. 
 
Assuming a GWAS in 𝑑1 interrogates each of the causal 
protein-coding genes with power (1 − 𝛽)  = 0.8, the 
expected number of causal, druggable targets (𝐸𝐶𝑇,𝑑1) 
identified by such a GWAS is given by: 
 
𝐸𝐶𝑇,𝑑1 =  𝑛𝐶𝑇,𝑑1 (1 − 𝛽) 
 
(where 𝑛𝐶𝑇,𝑑1 is the true number of causal, druggable targets 
in 𝑑1) 
 
𝐸𝐶𝑇,1 =  20 × 0.8 = 16 
𝑆𝐷𝐶𝑇,1 = √𝑛𝐶𝑇,𝑑1 𝛽 (1 − 𝛽) = 1.8 
 
The probability of a GWAS detecting 𝑥 =
 0, 1, 2, 3, 4 , …  all 20 of the available causal, druggable 
targets is again given by the binomial distribution: 
 
𝑃 (𝑥) = (
𝑛𝐶𝑇,𝑑1 
𝑥




𝑃 (𝑥) is the probability of detecting 𝑥 causal, druggable targets 
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𝑛𝐶𝑇,𝑑1  is the number of causal, druggable targets in disease 𝑑1 (20 
in this example) 
𝑛𝐶𝑇,𝑑1 − 𝑥 is the number of causal, druggable targets not detected 
in the GWAS 
(1 − 𝛽) is the power of the GWAS to detect a true association at a 
genetic locus (set at 0.8 in this analysis and assumed to be 
homogeneous for all loci) 
 
In summary, with 𝐶̅ = 100, 𝑃𝐶 =  
1
200
 , 𝑃𝑇  =  
1
5




, a GWAS with power 1 − 𝛽 = 0.8 at all loci would be 
expected to discover 16 (𝑆𝐷 1.8) of the 20 available, 
causal, druggable targets, on average.  Moreover, it would 
be extremely unlikely that a GWAS with (1 − 𝛽 = 0.8) at 
all loci, would discover fewer than 10 druggable targets.   
 
The exceedingly stringent type I error rate (𝛼) incorporated 
in such studies (e.g. 5 ×  10−8) also makes the probability 
of even one false target discovery being present among the 
declared associations very low indeed (Figure 3). These 
calculations suggest that adequately powered GWAS 
(designed with appropriate consideration of the distribution 
of genetic effect sizes, sample size and comprehensive 
coverage of sequence variation in protein coding genes) 
should provide a highly accurate and reliable way of 
specifying drug targets for human diseases, addressing the 
high 𝐹𝐷𝑅 problem that underpins inefficiency in drug 
development.   
 
 
Part 2: Probability of drug development success 
 
‘The Industry must rethink its process culture.  Success in 
the pharmaceutical industry depends on the random 
occurrence of a few ‘black swan’ products.’ 
 
- Bernard Munos. Lessons from 60 years of 
pharmaceutical innovation. Nature Rev. Drug 
Discov. 2009 8, 959–968 
 
If our assessment is accurate, the use of genomic 
information to support drug target identification should 
offer an opportunity to improve drug development success 
rates by bringing statistically robust, large-scale, 
randomised evidence from humans much earlier (even to the 
very start) of a drug development programme.  But is it 
possible to quantify what the improvement in drug 
development efficiency might be?   
Recent analyses have considered the influence of genomic 
evidence on drug development success rates but mainly 
from a retrospective viewpoint based on observed 
frequencies: e.g. ‘what are the observed rates of progression 
from one developmental phase to the next’ and, ‘to what 
extent have successful vs. unsuccessful drug development 
programmes had prior genetic support for the target?’  27 73.   
 
Instead, we consider: 
 
(a) The a priori probability of accurate target 
identification comparing orthodox (non-genomic) 
with genomic approaches.  
(b) The number of orthodox (non-genomic) drug 
development programmes that need to be pursued 
in parallel to ensure 90% probability of at least one 
licensing success 
(c) The probability of repurposing success 
(d) Preclinical target identification as a ‘predictive 
test’ for drug development success, comparing 
orthodox (non-genomic) with genomic approaches 
 
We then go on to use observed rates of preclinical and 
clinical development success to estimate the proportion of 
true target-disease relationships that are studied in 
contemporary drug development. Finally, we gauge the 
impact of the target selection step on ultimate success rate, 
which is necessary in orthodox (non-genomic) but not 
genomic preclinical development  
 





 preclinical drug development programmes yield 
licensed drugs1 2.  However, this estimate is based on the 
success rates of compounds rather than targets.  The success 
in early development of a first-in-class molecule for a given 
disease indication is often followed by a flurry of 
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development programmes, distributed across several 
companies, based on the same target and disease indication. 
The consequence is that multiple drugs may emerge, all in 
the same class (e.g. there are 7 different HMG coA 
reductase inhibitors (statins) licensed for lowering LDL-
cholesterol for coronary heart disease prevention, and >12 
different angiotensin converting enzyme inhibitors for the 
treatment of hypertension, heart failure and related 
conditions.  Using the ChEMBL database, we estimate a 
median of 2 (mean of 4) licensed drugs per efficacy target 
(Figure 4).  Therefore, the overall developmental success 













).   
 
Drug development success depends on correctly identifying 
a causal, druggable target-disease indication pairing, and 
then demonstrating the validity of the target in preclinical 
studies, and the efficacy of target modification in clinical 
trials.   
 
We showed previously (see Equation 6) that the a prior 
probability (𝑃𝐶𝑇) of selecting a disease-causing, druggable 
protein-disease pairing at random is: 
 
𝑃𝐶𝑇  =  𝛾𝐶𝑇 =  𝑃𝐶  ×  𝑃𝑇   
  
From Equations 3 and 5; 
 
𝑃𝐶  =   
?̅?
𝑁𝐺
  in the general case, or 𝑃𝐶 =  
𝐶
𝑁𝐺
  in the case of a 
specific disease, where 𝐶̅ = average number of causal 
genes per disease, and 𝐶 =the number of causal genes in the 
disease of interest. 
 
Thus, for a given disease: 
 






 )     
   
(Equation 7) 
      
Based on Equation 7,  𝛾𝐶𝑇  could be increased, in theory, by 
increasing 𝐶, increasing 𝑁𝑇, or by reducing 𝑁𝐺 .  
 
Table S2 and S3 illustrate the influence of different 
estimates of 𝐶 on the probability on 𝑃𝐶  =   𝛾𝐶 and 𝑃𝐶𝑇  = 
 𝛾𝐶𝑇 .  
 
𝐶, however, is not amenable to manipulation, being largely 
determined by evolutionary forces; 
𝑁𝐺, is also fixed;  
𝑁𝑇, however, could be increased by developing 
technologies that allow a broader range of gene products to 
be targeted therapeutically.  
 
It can be argued that the development of therapeutic 
monoclonal antibodies has already increased 𝑁𝑇 by 
permitting targeting of proteins that were not previously 
amenable to a small molecule therapeutic strategy74.  (The 
development of therapeutic antisense RNA and related 
technologies is likely to further extend future therapies into 
the RNA target space). 
 
However, there are also ways of reducing the number of 
genes under consideration in a given disease, so as to 
increase 𝛾𝐶𝑇 .   
 
Consider focusing solely on the druggable genome in a 
given disease. We can then write: 
 










𝛾𝐶𝑇 =  (
𝐶
𝑁𝐺
) × 1  
 
If 𝐶 = 100,  
 





Thus, among the set of druggable genes, all causal genes are 
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automatically both causal and druggable. Therefore, if 𝐶 =
100, the simple expedient of focusing target identification in 
a specific disease on the 4000 or so druggable genes, rather 









Alternatively, we could remove genes from consideration 
that we perceive to have a low probability of playing a 
causal role in the disease of interest, instead focusing on a 
subset of the genome 𝑁𝐶′, where 𝑁𝐶′ = the set of likely to 
be causal genes in the disease of interest. 
 
We could then write: 
 








If it were possible to enrich the sample space by 
progressively eliminating all non-causal while retaining all 
















     
 
Thus, in the limiting case, among an exclusively causal set 
of genes, the probability of being causal and druggable is 
simply the probability of being druggable (see Box 6 and 
Assumption 8).  
 
Eliminating non-causal while retaining causal genes is the 
crux of the target identification problem.  For reasons we 
outlined previously, an adequately powered GWAS in a 
disease of interest, with a stringent 𝛼 has the capability to 
exclude the non-causal while identifying the set of causal 
genes for any disease, of which 1/5th on average (
𝑁𝑇
𝑁𝐺
 ) is 
expected to be druggable under Assumption 8.  
 
In summary, the probability of selecting a causal, druggable 
target for a disease of interest based on a random pick from 
the whole genome is 
1
1000




based on a random pick from the druggable genome. We 
note that these probabilities from a random pick are not 




 for compounds (perhaps closer to 
2
100
 for novel 
targets).  In a later section, we show that these estimates are 
also similar in order to values for 𝛾𝐶𝑇 (the proportion of 
causal and druggable target-disease pairs available for 
discovery) calculated a posteriori from reported preclinical 
and clinical development success rates 2.    
 
Taken together, the calculations suggest that the current, 
mainly non-genomic preclinical approach to target 
identification only weakly enriches the sample space for 
causal target-disease pairings that are then taken forward 
into clinical development. 
 
Number of parallel development programmes required, 
to ensure 90% probability of at least one licensing 
success 
 
A common industry strategy to address low developmental 
success rates has been to pursue multiple drug development 
programmes in parallel, recognizing that the majority will 
fail, but that even a single success could ensure profitability 
because of revenues generated through the patent system. 
For example, 1120 unique pipeline drug programmes for 
Alzheimer’s disease were initiated across the industry in the 
period 1995 – 201475.  But, with the estimated current 
developmental success rate of around 2% for targets, on 
average, how many programmes would need to be pursued 
in parallel to have a 90% chance of at least one success?  
This can be calculated as follows. Let: 
 
 𝑃𝑠 =  within − programme success rate. 
 
Assuming all programmes are independent, the probability 





A 90% probability of at least 1 success equates to a 10% 
probability of no success in any programme (i.e. a 10% 
probability of all programmes failing) 
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𝑁 = 0.1  






Let us assume:  
 
𝑃𝑠 =  within − programme success rate













Thus, when 𝑃𝑠 =  0.02, industry needs to pursue 114 
independent programmes in parallel, on average, to have a 
90% probability of at least one developmental success; 34 
programmes would need to be pursued to have an 50% 
(evens) chance of at least one success.  Values of 𝑁 for a 
range of hypothetical values of 𝑃𝑠 are shown in Table S4. 
 
Probability of repurposing success 
Another approach to address poor drug development 
success rates is to try to identify new disease indications for 
drugs that failed to show efficacy for the original indication, 
but which have proved safe in man; or to expand indications 
for a drug already effective in one disease to another 
condition.  However, repurposing or indication expansion 
relies on the assumption that different diseases share at least 
some common drug targets.  How likely is this to be the 
case? 
 
Again, this can be tackled from a probabilistic perspective 
using two of the previous simplifying assumptions: 
 
Assumption 3: The probability of a protein influencing the 
pathogenesis of one disease is independent of the 
probability that it influences any other  
 
Assumption 8: The probability that a gene (protein) affects 
disease pathogenesis and the probability that a gene encodes 
a druggable protein is independent 
 
Repurposing or indication expansion can be considered 
from three perspectives: 
 
 How many diseases are likely to be influenced by 
the perturbation of a single therapeutic target? 
 How many diseases need to be considered for at 
least one pair to share a common therapeutic target, 
under the assumption of independence? 
 How many diseases need to be studied to find at 
least one that will be affected by pharmacological 
perturbation of a particular target of interest? 
 
Diseases influenced by perturbation of a single protein: We 
showed previously that the probability( 𝑃𝐶) of identifying a 
causal gene-disease pairing 𝐶𝐷 from the sample space 
comprising all genes and diseases, 𝐺𝐷, assuming 𝐶̅ = 100 













Under Assumption 3, the expected number diseases (𝐸𝐷) 
affected by any given gene is given by: 
 
𝐸𝐷 =  𝑃𝐶 × 𝑁𝐷 = 0.005 ×  10,000 = 50  
 
With standard deviation equal to: 
 
𝑆𝐷 =  √(1 − 𝑃𝐶) × 𝑃𝐶 ×  𝑁𝐷
= √0.995 ×  0.005 ×  10,000 = 7 
 
𝐸𝐷 declines the fewer diseases under consideration, or if 
𝐶̅ < 100. (Table S2). Since the estimate of 𝐸𝐷 should be 
precisely the same for a gene encoding a druggable as a 
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
19 
 
non-druggable target, under Assumption 8, it can be 
inferred that even the most specific of therapies is likely to 
influence a range of conditions; leading either to 
mechanism-based adverse effects, efficacy in more than one 
condition, or some combination of the two. In fact, under 
the assumptions above, perturbation of most therapeutic 
targets will affect between 36 and 64 diseases and only 1 in 
1000 targets would affect 28 or fewer conditions. 
 
Shared therapeutic targets: The second question is akin to a 
well-known statistical problem of how many people need to 
be assembled for at least one pair to share the same 
birthday. 
 
Consider two diseases. Again, we assume 𝐶̅ = 100. The 
first disease in the pair could have any 100 of the 20,000 
genes in the genome as its causal set.  The probability of the 
second disease sharing a number 𝑥 of the 100 genes already 














So, the probability that they do not share any gene is: 
 











If we study a third disease, the probability of that disease 
not sharing any of the 200 genes involved in the previous 














So, the probability of the third disease not sharing a single 
gene with the other two (𝑥2= 0) is: 
 











So the total probability of the three diseases not sharing any 
of the genes is: 
 
𝑃(𝑥1 = 0)  ×  𝑃(𝑥2 = 0)  =  0.605 ×  0.365 = 0.221 
 
With four diseases, the probability of none of them sharing 
a gene is < 5%, and for eight diseases it is less than 1 in a 
million: it is almost certain that at least two diseases from 
this pool of eight, will share at least one common 
susceptibility gene. 
 
Number of diseases that need to be studied to identify at 
least one that is affected by perturbation of a given target: 
The answer to the third question follows the same reasoning 
as that used previously to estimate the number of drug 
development programmes that need to be pursued in parallel 
to have at least a 90% or greater chance of at least one 
development success.  With 𝑃𝐶 =
1
200
 (i.e. focusing on the 
druggable genome), 459 diseases would need to be studied 
to have ≥ 90% chance of identifying at least one condition 
that is causally affected by perturbation of a particular target 
of interest. If  𝐶̅ = 1000, the number of diseases that need 
to be studied is 45.   
 
Despite these considerations, the ultimate challenge for 
repurposing remains the same as that for de novo drug 
development: knowing precisely which targets are important 
in which diseases and therefore which targets are shared 
among a set of diseases of interest. This, we believe, can 
only be tackled systematically by the genomic approach we 
have described in previous sections. 
 
Preclinical target identification as a ‘predictive test’ for 
drug development success 
  
We next reduce drug development to a two-stage process: a 
preclinical component whose function is to predict target-
disease pairings destined for clinical phase success (stage 
1), and a clinical component (stage 2) whose function is to 
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evaluate target-disease pairings brought forward from stage 
1. Success in stage 2 is thus dependent on the predictive 
performance of stage 1. 
 
Since clinical drug development failure, a consequence of 
incorrect target specification, currently accounts for around 
two in every three late-stage failures 22 28, we introduce one 
further simplifying assumption. 
 
Assumption 9.  Inaccurate target selection is the exclusive 
reason for clinical phase (stage 2) drug development failure.   
 
Key variables in the following section are indexed by the 
lower-case suffix 𝑝𝑐 to denote preclinical and the lower case 
suffix 𝑐 to denote clinical stage development.  
 
Possible outcomes from pre-clinical and clinical phase 













𝑇𝑃𝑝𝑐 = 𝛾𝑝𝑐(1 − 𝛽𝑝𝑐)  𝐹𝑃𝑝𝑐 = 𝛼𝑝𝑐(1 − 𝛾𝑝𝑐)  𝑆𝑝𝑐  
Declared 
 failure 
𝐹𝑁𝑝𝑐 = 𝛾𝑝𝑐𝛽𝑝𝑐  𝑇𝑁𝑝𝑐 = (1 − 𝛼𝑝𝑐)(1 − 𝛾𝑝𝑐)  1 − 𝑆𝑝𝑐  











𝑇𝑃𝑐 = 𝛾𝑐(1 − 𝛽𝑐)  𝐹𝑃𝑐 = 𝛼𝑐(1 − 𝛾𝑐)  𝑆𝑐  
Declared  
failure 
𝐹𝑁𝑐 = 𝛾𝑐𝛽𝑐  𝑇𝑁𝑐 = (1 − 𝛼𝑐)(1 − 𝛾𝑐)  1 − 𝑆𝑐  
 𝛾𝑐 = 𝑇𝐷𝑅𝑝𝑐 1 − 𝛾𝑐  1 
 
𝛾 = proportion of true target-disease relationships  
𝑇𝑃 = true positive rate 
𝐹𝑃 = false positive rate 
𝑇𝑁 = true negative rate 
𝐹𝑁 = false negative rate 
𝑆 = declared success rate 
1 − 𝑆 = declared failure rate 
 
 
Declared preclinical successes (𝑆𝑝𝑐) comprise both true and 
false positive findings. Therefore: 
 
𝑆𝑝𝑐 = 𝑇𝑃𝑝𝑐 +  𝐹𝑃𝑝𝑐 = 𝛾𝑝𝑐(1 − 𝛽𝑝𝑐)   + 𝛼𝑝𝑐(1 − 𝛾𝑝𝑐) 
 
The proportion of true positive findings among reported 
preclinical successes equates to the preclinical true 










𝛾𝑝𝑐(1−𝛽𝑝𝑐)  + 𝛼𝑝𝑐(1−𝛾𝑝𝑐)
 
 
 (𝐹𝐷𝑅𝑝𝑐 = 1 − 𝑇𝐷𝑅𝑝𝑐)  
 
If a clinical phase drug development programme follows 
every declared preclinical success, the proportion of true 
target disease relationships in clinical phase development is 
equivalent to the preclinical true discovery rate, so we can 
write: 
 
𝛾𝑐 = 𝑇𝐷𝑅𝑝𝑐 
(Equation 8)  
 
Similarly, for clinical phase (stage 2) development: 
 
𝑆𝑐= 𝑇𝑃𝑐 +  𝐹𝑃𝑐 = 𝛾𝑐(1 − 𝛽𝑐)   + 𝛼𝑐(1 − 𝛾𝑐) 
 










Since 𝛾𝑐 = 𝑇𝐷𝑅𝑝𝑐 (Equation 8)   
       
𝑇𝐷𝑅𝑐  = 
𝑇𝐷𝑅𝑝𝑐 (1−𝛽𝑐)





𝑆𝑐 =  𝑇𝐷𝑅𝑝𝑐(1 − 𝛽𝑐)   +  𝛼𝑐(1 − 𝑇𝐷𝑅𝑝𝑐)  
E 
These equations underline the close mathematical 
relationship between preclinical and clinical discovery and 
success rates, which can be formalised as follows: 
 
𝑇𝐷𝑅𝑐  = 
𝑇𝐷𝑅𝑝𝑐 (1−𝛽𝑐)
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Dividing the numerator and denominator by 𝑇𝐷𝑅𝑝𝑐 (1 − 𝛽𝑐)  
and then rearranging: 
 




































































Equation 10 illustrates that the clinical phase discovery rate 
can be resolved mathematically into terms that encompass 




preclinical phase power and false positive rate (the term 
𝛼𝑝𝑐
1−𝛽𝑝𝑐




).  In this sense, Equation 10 can be conceived as 
a mathematical summary of the probabilities and parameters 
determining drug development success. 
 
Consider orthodox non-genomic preclinical (stage 1) drug 
development programmes with base case parameters 
defined by the sample space, 𝑁𝐺 × 𝑁𝐷 where: 
 
𝑁𝐺   =  Total number of protein − coding genes =  20,000  
𝑁𝐷  =  Total number of complex human diseases =  10,000  
𝐶̅ =  Average number of causal genes per disease =  100  
𝑁𝑇 =  Total number of genes encoding druggable targets 
=  4000 
 
From Equation 7, we can infer that; 
 











Setting 𝛼𝑝𝑐 and 𝛽𝑝𝑐 to 0.05 and 0.2 respectively, as is as 
standard for (non-genomic) preclinical experiments, and 
assuming it were somehow possible to evaluate every 
protein in every disease in such studies, then 𝑇𝐷𝑅𝑝𝑐  =
 0.016 and 𝐹𝐷𝑅𝑝𝑐  =  0.984.  𝑇𝐷𝑅𝑝𝑐  increases to 0.14 and 
the 𝐹𝐷𝑅𝑝𝑐  falls to 0.86 if 𝐶̅ =  1000 (𝛾𝑝𝑐 =
1
100
), but the 




) (Table 2).    
 
In striking contrast, with the same sample space but a 
genomic approach to target identification, where (1 − 𝛽)  =
0.8, 𝛼 = 5 ×  10 −8 and all 20,000 targets encoded by the 
genome are, by definition, interrogated simultaneously, 
𝑇𝐷𝑅𝑝𝑐 = 0.999, and 𝐹𝐷𝑅𝑝𝑐 = 0.001. This is a reversal of 
𝑇𝐷𝑅𝑝𝑐 and 𝐹𝐷𝑅𝑝𝑐values when compared to the orthodox 
(non-genomic) preclinical approach.   The performance of 
genomic studies for target identification, based on these 
values of 𝛼 and 1 − 𝛽, is little affected by 100-fold 
differences in 𝐶 ̅ and 𝛾𝑝𝑐 (Table 2).  
 
As we showed previously, if sampling were restricted to the 
a sample space demarcated by the druggable genome, 𝑁𝑇 ×
𝑁𝐷, where; 
 
𝑁𝐷  =  Total number of complex human diseases =  10,000  
𝑁𝑇 =  Total number of genes encoding druggable targets =
 4000  
𝐶̅ =  Average number of causal genes per disease =  100  
𝑁𝑇𝐷   =  Total number of possible druggable gene
− disease pairs = 4,000 ×  20,000 
=  40 x 106 
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Focusing orthodox (non-genomic) preclinical studies on this 
restricted sample space (with conventional values for 𝛼 and 
1 − 𝛽) marginally increases the 𝑇𝐷𝑅𝑝𝑐(from 0.016 to 0.08) 
and reduces 𝐹𝐷𝑅𝑝𝑐 but also only marginally (from 0.998 to 
0.920).  Applying the genomic approach in the same sample 
space, where (1 − 𝛽)  = 0.8, and 𝛼 = 5 ×  10 −8, and all 
4,000 druggable targets encoded by the genome are 
interrogated simultaneously, the already high 𝑇𝐷𝑅𝑝𝑐  
increases to 0.9999, and the already low 𝐹𝐷𝑅𝑝𝑐 would fall 
further to 0.0001. (Table 2). 
 
It might be argued that  𝑇𝐷𝑅𝑝𝑐 and 𝑆𝑝𝑐 in conventional 
(non-genomic) preclinical pipelines could also be enhanced 
by simply setting a more stringent false positive rate in 
experiments involving cells, tissues and animal models.  
This is correct, but the change would have practical 
consequences. Very substantial increases in sample size 
would be required to maintain power. This might be 
perceived as being at odds with efforts to reduce the number 
of animals used in medical research, for example. However, 
in the long run, larger, more definitive large-scale animal 
experiments conducted early in the exploration of a 
hypothesis might actually make an important contribution to 
the goal of reducing the number of animals sacrificed, by 
minimizing wasted research. However, attending to the type 
1 error rate issue alone fails to address the problem of the 
questionable validity of many animal models of human 
disease. It is also predicated on being able to evaluate every 
protein in every disease, a task we know to be beyond the 
capability of orthodox (non-genomic) preclinical studies 
based on cells, tissues and animal models. We return this 
issue in a later section. 
 
Turning now to clinical (stage 2) development, 𝛼𝑐 and 
1 − 𝛽𝑐 are typically set to 0.05 and 0.8 respectively, so it is 
also possible to examine the influence of variation in 𝛾𝑝𝑐, 
𝛼𝑝𝑐 and 𝛽𝑝𝑐 on preclinical (𝑆𝑝𝑐), clinical ( 𝑆𝑐  ) and overall 
success (𝑆𝑜 = 𝑆𝑝𝑐  ×  𝑆𝑐), using Equations 9 and 10. The 
results are summarised in Table 2. 
 
For orthodox (non-genomic) preclinical development, with 
sampling from the whole genome (where 𝐶̅ = 100, 1 −
𝛽𝑝𝑐 = 0.8, 𝛼𝑝𝑐 = 0.05, 𝛾𝑝𝑐 =
1
1000 
), 𝑆𝑝𝑐 = 0.05 (𝑇𝐷𝑅𝑝𝑐 =
0.016; 𝐹𝐷𝑅𝑝𝑐  =  0.984) and 𝑆𝑐 =  0.06 (𝑇𝐷𝑅𝑐 =0.2; 
𝐹𝐷𝑅𝑐 = 0.8) giving an overall declared drug development 
success rate 𝑆𝑜 = 𝑆𝑝𝑐 × 𝑆𝑐 = 0.003 (Table 2). 
 
With the same parameters (𝐶̅ = 100, 𝛾𝑝𝑐 =
1
1000 
), but with 
the genomic approach replacing orthodox non-genomic 
preclinical programmes, 𝑆𝑝𝑐 = 0.0008 (𝑇𝐷𝑅𝑝𝑐 =
0.99994; 𝐹𝐷𝑅𝑝𝑐  =  0.00006), 𝑆𝑐 =  0.79995 (𝑇𝐷𝑅𝑐  =
0.999996; 𝐹𝐷𝑅𝑐 = 0.000004), and  𝑆𝑜 = 0.00064.    
 
It may at first seem surprising that 𝑆𝑝𝑐 (and 𝑆𝑜) is actually 
lower for genomic than orthodox (non-genomic) stage 1 
development, because of a higher stage 1 ‘failure’ rate. 
However, a ‘failure’ in a GWAS simply refers to a null 
association with the disease of interest of a specific gene 
(from all 20,000 evaluated), which is very different from 
the expensive failure of a lengthy orthodox preclinical 
development programme focusing on a single target at a 
time. The high ‘failure rate’ (i.e. high rate of null 
associations) in GWAS reflects the much more stringent 
𝛼𝑝𝑐 in this type of study design, which results in a much 
lower 𝐹𝐷𝑅𝑝𝑐 and much higher 𝑇𝐷𝑅𝑝𝑐. Since 𝑇𝐷𝑅𝑝𝑐= 𝛾𝑐, 
the GWAS design ensures fewer false relationships are 
carried forward into clinical development when compared to 
the non-genomic approach.  Consequently, 𝑇𝐷𝑅𝑐  is much 
increased with the genomic (compared to non-genomic) 
preclinical target identification.  In summary, the 
calculations indicate that a genomic approach to preclinical 
target validation has the potential to reverse the probability 
of drug development success when compared to the 
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Estimating the proportion of true target-disease 
relationships currently studied based on observed 
development success rates 
 
The preceding estimates of 𝛾𝑝𝑐 and the corresponding 
estimates of 𝑆, 𝐹𝐷𝑅 and 𝑇𝐷𝑅 are based on naïve pairings of 
genes (or proteins) and diseases (selection at random), using 
the sample spaces defined by common human diseases and 
either the whole genome or the druggable genome. But how 
closely do these estimates reflect current drug development?  
 
Since observed values for 𝑆𝑝𝑐 and 𝑆𝑐  have been reported 
2 28, 
it should be possible to make a posteriori estimates of 𝛾𝑐 
and 𝛾𝑝𝑐 and other relevant metrics, and compare them to the 
a priori estimates based on a random pick of target-disease 
pairings in the sample space.  
 
Both 𝛾𝑐 and 𝛾𝑝𝑐 can be estimated from observed preclinical 
and clinical success rates as follows: 
 
 
𝑆𝑐= 𝑇𝑃𝑐 +  𝐹𝑃𝑐  
 
𝑆𝑐= 𝛾𝑐(1 − 𝛽𝑐)   +  𝛼𝑐(1 − 𝛾𝑐)   
 
𝑆𝑐= 𝛾𝑐 − 𝛽𝑐𝛾𝑐 + 𝛼𝑐 − 𝛼𝑐𝛾𝑐 
 
𝑆𝑐 − 𝛼𝑐  = 𝛾𝑐 − 𝛽𝑐𝛾𝑐 − 𝛼𝑐𝛾𝑐 
 











We previously established (Equation 8) that  
 
 
𝛾𝑐 = 𝑇𝐷𝑅𝑝𝑐 =  
𝑇𝑃𝑝𝑐
𝑆𝑝𝑐
     
 



















The reported clinical success rate 2 28, 𝑆𝑐 = 0.1 
 
Assuming 𝛼𝑐 = 0.05, 𝛽𝑐 = 0.2 (commonly used false 


























𝑇𝐷𝑅𝑐  = 0.56 
 
 
𝐹𝐷𝑅𝑐 = 1−0.56=0.44 
 
 
This calculation suggests that nearly one in two declared 
clinical trial successes may be a false discovery. 
 
Since 𝛾𝑐 = 𝑇𝐷𝑅𝑝𝑐  and 𝑇𝐷𝑅𝑝𝑐 = 1 − 𝐹𝐷𝑅𝑝𝑐 
 
𝑇𝐷𝑅𝑝𝑐 = 0.0667  
 
𝐹𝐷𝑅𝑝𝑐 = 1 − 0.0667 = 0.9333 
 
These a posteriori estimates for 𝑇𝐷𝑅𝑝𝑐 and 𝐹𝐷𝑅𝑝𝑐 are of a 









The reported preclinical success rate 2, 𝑆𝑝𝑐 = 0.4 
 
Using the value 𝛾𝑐 = 0.0667, and setting power for 
preclinical studies at (1 − 𝛽𝑝𝑐) = 0.8, we have: 
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𝛾𝑝𝑐 = 0.03335  
 
 
In estimating 𝛼𝑝𝑐, we use the following: 
 
𝑆𝑝𝑐 = 𝑇𝑃𝑝𝑐 +  𝐹𝑃𝑝𝑐  
 
𝑆𝑝𝑐= 𝛾𝑝𝑐(1 − 𝛽𝑝𝑐)   +  𝛼𝑝𝑐(1 − 𝛾𝑝𝑐)   
 
𝑆𝑝𝑐= 𝛾𝑝𝑐 − 𝛽𝑝𝑐𝛾𝑝𝑐   + 𝛼𝑝𝑐 −  𝛼𝑝𝑐𝛾𝑝𝑐   
 
𝛼𝑝𝑐 − 𝛼𝑝𝑐𝛾𝑝𝑐 = 𝑆𝑝𝑐 − 𝛾𝑝𝑐 + 𝛽𝑝𝑐𝛾𝑝𝑐 
 







Note: the term 𝑆𝑝𝑐 − 𝛾𝑝𝑐(1 − 𝛽𝑝𝑐) = 𝑆𝑝𝑐 − 𝑇𝑃𝑝𝑐 = 𝐹𝑃𝑝𝑐  
 
 
Therefore 𝛼𝑝𝑐 = 
𝐹𝑃𝑝𝑐
(1− 𝛾𝑝𝑐)
(see embedded table) 
 
 
With 𝑆𝑝𝑐 = 0.4; 𝛾𝑝𝑐 = 0.03335; and 1 − 𝛽𝑝𝑐 = 0.8; 
 
𝛼𝑝𝑐 = 0.386  
 
 
Values of 𝛾𝑝𝑐 and 𝛼𝑝𝑐 for a range of values for 1 − 𝛽𝑝𝑐 from 
0.2 to 0.8, and a fixed value of 𝛾𝑐 = 0.067, are illustrated in 
Figure 5. For values of 1 − 𝛽𝑝𝑐, in this range, values for 𝛾𝑝𝑐 
lie in the range 0.033 to 0.133, representing 6.5-fold to 26.5-
fold enrichment of true relationships over a random pick 
from a sample space demarcated by all diseases and the 
druggable genome (𝛾𝑝𝑐 =
1
200
 = 0.005). Although these 
enrichment rates for established preclinical drug 
development appear substantial, the very low values of 𝛾𝑝𝑐 
mean that they are insufficient to prevent a large proportion 
of false target-disease relationships being pursued during 
clinical phase development, which accounts for the low 
rates of clinical success, and the possibility that a large 




The impact of the target selection step in orthodox (non-
genomic) preclinical development on rug development 
success  
 
The calculations presented thus far assume that it is possible 
for orthodox (non-genomic) studies based on cells, tissues 
and animal models to evaluate every protein in every 
disease but, in contrast to the genomic approach, this is 
clearly not feasible. Although numerous orthodox (non-
genomic) preclinical programmes, investigating scores of 
targets at a time, can and do proceed in parallel, the number 
of such parallel target evaluation programmes is limited by 
logistics and cost.  This imposes the need for a selection 
step in which a subset of targets must first be prioritized for 
inclusion in a small number of parallel early phase drug 
development programmes. By contrast a GWAS for target 
identification, by definition, interrogates every target in 
parallel.    
 
This selection step in standard (non-genomic) preclinical 
drug development therefore introduces a further probability 
consideration.   
 
The probability that 0, 1, 2, … 𝐴 causal targets is present in a 
sample of size 𝑁 (where each member of the sample 
corresponds to an independent development programme 
based on a different drug target and encoding gene), drawn 
without replacement from the pool of 4000 druggable genes 
(proteins), of which 𝐶 are causal for the disease of interest, 
















The expected number of causal, druggable targets 𝐸(𝐴) in 
the sample is given by: 
 
𝐸(𝐴) = 𝑁 (
𝐶
4,000





Expected values for A based on a range of values of N and C 
are shown in Table S3.  Unless 𝑁 is very large (e.g. 200 
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independent preclinical programmes proceeding in parallel, 
each evaluating a different target), there is a very low 
probability of a causal, druggable target being included in 
the set selected for preclinical studies, based on a random 
pick. This emphasises the need for very strong priors before 
embarking on a drug development programme. 
 
However, there are yet further considerations.  Let us 
assume that a company pursues all 𝑁 targets in parallel 
preclinical programmes.  A true causal target in the sample 
will have a probability of being correctly detected (true 
positive rate) corresponding to the power of the relevant 
experiments (1 − 𝛽). The probability of a non-causal target 
being erroneously inferred as causal is given by the 
experimental Type 1 error rate (𝛼).  The probability of 
missing a causal, druggable target is the false negative rate 
(𝛽), while the probability of correctly excluding a non-
causal, druggable target (true negative rate) is (1 − 𝛼).   
As previously shown in Figure 3, for any given disease, the 
druggable genome can be resolved into components 
comprising genes that encode causal, druggable targets 
(previously estimated as around 20 per disease), and 
druggable but non-causal targets for that particular disease 
(estimated as 3980).  If all N parallel preclinical 
programmes in the sample progress to completion, four 
outcomes are possible: a) one or more true positives is 
correctly identified with no false positives; b) a mixture of 
one or more true and false positives emerge; c) there are no 
positive findings; or, d) in a worst-case scenario, one or 
more false positive results emerge with no true positives.   
 
Let us imagine that one nominally positive target is pursued 
for clinical development under the three scenarios that 
generate positive findings from preclinical studies 
(regardless of whether they are true or false positives), and 
that correct target selection is the only barrier to eventual 
drug development success (Assumption 9).  Under the first 
scenario, clinical development will always be successful, 
under the second it will sometimes be successful and under 
the fourth never successful.  Consider a thought experiment 
in which a large number of companies repeat the same 
process so as to generate a frequency distribution of 
eventual company successes.  The probabilities of eventual 
development success in this hypothetical drug development 
world are given by equations in the Appendix 2 and the 
results are shown in Table S5 and Figure 6.  Assuming 
there are 20 causal, druggable targets to find, increasing the 
number of parallel preclinical programmes from 20 to 50 to 
200 has a modest impact on drug development success if 
these are picked from the full set of 4000 druggable 
proteins.  However, if it were possible to obtain reliable 
biological information on the relevance (or not) of selected 
targets, such that the sampling frame could be reduced in 
size to 2000, 1000, or perhaps even 200 targets, while 
retaining all 20 causal targets in the sample, success rates 
would improve. 
 
Figure 6 shows the relationship between the expected 
number of true and false positive findings, the number of 
causal, druggable targets in the original sampling frame, and 
the total number of trials.  It is relevant that no matter how 
many parallel drug development programmes are 
undertaken, the expected number of true positives will only 
be greater than the number of false positives if the set of 
targets in the sampling frame is relatively low (< 400 
targets) and all causal, druggable targets are retained in the 
sample.  Clinical phase development programmes therefore 
need to be supported by extremely strong priors. As we 
argue here, genomic evidence provides compelling 
biological priors for the full set of 4000 drugggable targets 
each time a GWAS is done in a particular disease. 
 
Therefore, on the assumption that incorrect target 
specification is the overarching reason for drug 
development failure, these considerations go a long way 
towards explaining the currently low rates of drug 
development success.   They also indicate that the genomic 
approach to drug target identification should outperform the 
orthodox non-genomic approach to preclinical drug 
development at least by several orders of magnitude, even 
providing the potential to reverse the odds of drug 
development success.   
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Part 3: Assumptions, parameters and limitations 
 
‘Seek simplicity and mistrust it’ 
- Alfred North Whitehead, In The Concept of 
Nature (1919), Chapter VII, p.143 
 
‘Your assumptions are your windows on the world. Scrub 
them off every once in a while, or the light won’t come in’ 
 
- Attributed to Isaac Asimov and Alan Alda 
 
The inferences we have drawn depend on the validity of our 
assumptions, and on the parameters we used to calculate the 
various probabilities. We now explore these in more detail 




Assumption 1: Each gene encodes a unique protein with a 
single function 
 
We assumed a 1:1 relationship between genes and proteins, 
implicitly arguing that any protein has a single function, 
echoing the historic one-gene one-protein hypothesis of 
Beadle and Tatum76.  However, genes can encode 
alternative mRNA transcripts, some of which may be 
translated into different proteins77.  Ensembl (v.87) contains 
22,264 protein coding genes encoding 87,662 transcripts. 
Post-translational modifications increase the complexity of 
the proteome while some proteins may also contain domains 
that serve distinct functions78. Other proteins, referred to as 
‘moonlighting proteins’ appear to have the ability to 
undertake alternative functions depending on the cellular 
context, even in the absence of splice variants or distinct 
functional domains79. Moreover, some drugs may interact 
with a protein-binding pocket composed of elements of two 
or more protein subunits, each encoded by a different gene.  
(An example is the benzodiazepine class of drugs that bind 
to GABA-A receptors at the interface of two of its 
subunits).  Thus, the assumed 1:1 relationship between 
genes, proteins, protein functions and drug targets, is an 
undoubted simplification, posing an additional challenge for 
drug development to not only target the right protein, but 
also the correct subtype and isoform, sometimes in the right 
cellular context.  
 
Assumption 2: A given protein can influence the risk of 
more than one disease  
 
It has been estimated that nearly 20% of the genes and 5% 
of the SNPs currently curated by the GWAS catalogue 
exhibit (pleiotropic) associations with more than one trait80  
and that many human traits share common genetic 
influences. 81 82  For example, variants in GCKR (type 2 
diabetes, non-alcoholic steatotic hepatitis, uric acid, glucose, 
triglycerides), IL6R (coronary heart disease, asthma, 
abdominal aortic aneurysm) and SH2B3 (haemopoetic traits, 
low-density lipoprotein (LDL)-cholesterol concentration, 
blood pressure, autoimmune conditions, and coronary heart 
disease) have been associated with diverse diseases and 
traits.  Although the potential mechanisms underlying 
pleiotropic associations are numerous83, one explanation is 
that a single protein might play a controlling role in several 
pathophysiological processes.  Since a proportion of such 
genes could encode druggable targets, the corollary is that 
treatments proven to be effective in one disease have the 
potential to be successfully repurposed for another. Prior 
examples of repurposing successes and broadening of 
treatment indications also support this assumption (Table 
5).  A further consequence is that drugs used to treat one 
disease could have adverse effects on other conditions, 
depending on the direction of effect. For example, it is 
known now that statins, which inhibit HMG-coA reductase 
reduce the risk of coronary heart disease by lowering LDL-
cholesterol.  However, they also modestly increase risk of 
type 2 diabetes, an effect shown by Mendelian 
randomisation to be mechanism-based84.  By implication, 
study designs that interrogate the association of variants in 
genes encoding a druggable target with a broad range of 
disease biomarkers and clinical diagnoses in parallel 
(sometimes called phenome wide association analysis – 
PheWAS85) should offer a systematic and comprehensive 
means to identify repurposing and indication expansion 
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opportunities, as well mechanism-based adverse effects. We 
return to this point in a later section. 
 
Assumption 3: The probability of a protein influencing the 
pathogenesis of one disease is independent of the 
probability that it influences any other  
 
We have shown that even in the presence of this 
‘independence’ assumption, it is highly likely that diseases 
share causal proteins, as supported by evidence from 
GWAS82, providing one explanation for the observation of 
genetic pleiotropy.  
 
In reality, the independence assumption is very likely to 
breakdown for certain groups of diseases, with one 
consequence being that certain disease groups are even 
more likely to share common targets, offering increased 
opportunity for therapeutic repurposing.  Autoimmune 
diseases provide some of the clearest examples.  As an 
illustration, monoclonal antibody therapeutics that target 
tumour necrosis factor- for treatment of rheumatoid 
arthritis, also show efficacy in inflammatory bowel 
diseases86.  Ustekinumab, a monoclonal antibody that 
targets interleukin-12/23 receptor developed for psoriasis 
also shows efficacy in inflammatory bowel disease87. Other 
examples are provided by conditions that might, at first 
sight, appear to be less likely to share a therapeutic target. 
For example, monoclonal antibodies targeting vascular 
endothelial growth factor have found use in the treatment of 
age-related macular degeneration as well as certain cancers, 
and it is now known that the pathogenesis of both diseases 
involves angiogenesis88.  However, such agents also raise 
blood pressure and increase risk of thrombotic vascular 
events as a consequence of their mechanism of action89.   
 
If diseases related by common mechanism were to be 
grouped as adjacent columns in the sample space (Figure 
1), and the genes encoding functionally related proteins as 
adjacent rows, with the sample space being marked using 
contours corresponding to probabilities of any target-disease 
paring being disease-causing, then ridges and troughs of 
higher and lower probability would be observed to emerge 
from an otherwise flat, homogenous probability space that 
corresponds to the independence assumption.  In due course, 
we believe the genetic approach we describe will uncover 
more diseases with common underpinning, that this will 
enable reconfiguration of gene and disease relationships in 
the sample space, and will support more rational medication 
repurposing and indication expansion programmes90. 
Nevertheless, at present, given the very broad spectrum of 
human diseases, we consider our simplifying assumption to 
serve as a useful start point for the concepts we develop and 
calculations we make.  
  
Assumption 4: Drug treatments for human disease target 
proteins encoded in the germ line. 
 
We excluded from consideration the treatment of many 
infectious diseases, where proteins in the pathogen rather 
than the host are the therapeutic targets, as well as cancer, 
where treatment targets are mutated or aberrantly expressed 
proteins encoded by the abnormal genome of the cancer 
cell. However, with these restrictions, proteins encoded by 
the germ line serve as the therapeutic targets of >80% of 
licensed drugs91 92.  This simplifying assumption is therefore 
robust for the sample space as we define it.  
 
Assumption 5: DNA sequence variants in and around a 
gene encoding a drug target, that alter expression or 
activity of the encoded protein (cis-acting variants) are 
ubiquitous in the genome 
 
GWAS of mRNA expression and protein concentration 
provide hundreds of empirical examples of SNPs 
influencing the expression of nearby genes (acting in cis) 
leading to the concept of expression (e) and protein (p) 
quantitative trait loci (QTL)93 94 95 96 97 98.  Recently, the 
ENCODE, ROADMAP and GTEX projects have 
catalogued variants with functional effects on both local 
(cis) and distant (trans) gene expression in a variety of cell 
types and tissues99 100 101.  As datasets enlarge and improved 
proteomics platforms encompass a broader set of human 
proteins, we anticipate the catalogue of cis pQTLs will 
expand, providing a larger armamentarium of such variants 
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in genes encoding druggable targets that serve as important 
tools for drug target identification and validation.  
 
Assumption 6: The association of cis-acting variants with 
biomarkers and disease end-points in a population genetic 
study accurately predict the effects of pharmacological 
modification of the encoded target in a clinical trial  
 
The reliability of this assumption has been demonstrated by 
comparisons of the associations of cis-acting variants in 
genes encoding the targets of licensed drugs in population 
studies, and the effect of treatments targeting the same 
protein in clinical trials, using a common set of biomarkers 
and disease outcomes as the readout. Applied examples of 
this paradigm have now been used to predict the eventual 
failure in clinical trials of first-in-class drugs for prevention 
and treatment of cardiovascular disease102 103, to separate 
on- from off-target effects of drugs84 104, and to identify 
indication expansion opportunities for established drugs 105.  
This concordance may seem surprising given that drugs 
typically target the action of proteins while variants 
identified by GWAS are typically non-coding, probably 
influencing mRNA and thence protein expression.  
Nevertheless, the empirical findings are compelling, with 
recent studies indicating that the concordance between the 
effects of genetic variants and drugs targeting corresponding 
proteins can extend across scores of biomarkers and disease 
end-points106. These proof-of-concept examples (Appendix 
1) now provide strong motivation for scaling the approach 
to interrogate the association of cis-acting variants in all 
druggable genes against the full spectrum of diseases and 
biomarkers in parallel.   
 
Coding region (loss- and gain-of-function) variants have 
also been shown to be useful tools for drug target selection 
and validation107 108. As falling costs lead to an expansion in 
sequencing studies, including in populations with a high 
rates of consanguinity, thereby enriched for homozygous 
loss of function variants109 110, we also anticipate that a 
broader spectrum of druggable genome variation will be 
discovered encompassing rare, low frequency and common 
variants in both coding regions (influencing function) and 
non-coding regions (influencing expression) that, when 
linked to phenotype and disease outcome, will provide 
invaluable information for target identification and 
validation. 
 
Assumption 7: Genotyping arrays used in GWAS provide 
comprehensive, appropriately powered coverage of the 
genome, and associations discovered at any one gene are 
independent of those detected at any other 
 
We have made the assumption that the genotyping arrays 
used in GWAS provide comprehensive coverage of all 
genes (including all druggable genes), that all such studies 
are conducted such that power is 0.8 at all loci, with 𝛼 =
5 × 10−8, and that the discovery of any one genetic locus is 
independent of any other. We recognise that in reality, 
power in many GWAS is likely to be much lower than 0.8 
suggesting that additional loci are likely to be identified by 
increased sample size. We also recognise that the local 
correlation between SNPs (linkage disequilibrium; LD) can 
lead to ambiguity on the source of the association signal(s) 
at any locus identified by a GWAS (placing uncertainty on 
the role of any implicated drug target).   We showed 
previously that GWAS to date have identied LD regions 
containing a single druggable gene in around 10.5% of 
cases67, and 31.9% of such LD regions contain 2 or more 
genes, at least one of which encodes a druggable target.  
However, to begin to address the issue of verifying the 
causal gene(s) in an associated region, sequencing projects 
have led to haplotype reference panels that enable dense 
imputation and fine mapping of association signals111. In 
silico approaches based on functional annotation of the 
genome have been developed, as have statistical-, pathway-, 
and eQTL- co-localisation methods, to address this problem, 
together with scoring systems that assimilate results from 
multiple methods with various degrees of weighting112.   An 
alternative approach to elucidation of causal signals with 
translational potential is to flip the problem by focusing 
genetic association studies exclusively on cis-acting variants 
within the druggable genome – ‘druggable genome wide 
association studies’.  To that end, we recently designed the 
content of a new genotyping array, with dense marker 
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coverage of genes encoding druggable targets67, facilitating 
a gene-centric approach to disease association studies for 
drug development.  The array design also enables gene-
based, not just SNP-based, association tests. The inclusion 
of common, non-coding as well as less frequent coding 
variation, should also enable the construction of allelic 
series113 (the genetic counterpart of a pharmacological dose 
response relationship). 
 
Assumption 8: The probability that a protein affects 
disease pathogenesis and the probability the protein can be 
targeted by a drug is independent 
 
This assumption is more speculative.  An argument could be 
made that genes included in our recent update of the 
druggable genome67 that encode the protein targets of small 
molecule drugs are more likely than other genes to be 
disease causing.  This is because druggability predictions 
are based, in part, on membership of protein families 
containing licensed drug targets that, by definition, are both 
druggable and play a controlling role in disease 
susceptibility. However, this bias should not apply to the 
2000 or so genes that were included in the druggable set 
because of sequence similarity to drugged proteins, or 
because they encode extracellular regions that are targetable 
by monoclonal antibodies67.  Moreover, the converse 
argument is equally plausible that druggable genes are less 
likely than others to be pathogenic, because the druggable 
set is enriched for proteins with natural ligands that sub 
serve key cellular functions.  Evolutionary forces might 
therefore exert purifying selection on deleterious variants in 
such genes, if they were to affect reproductive fitness. 
Empirical evidence on this issue is limited.  In our own 
recent analysis using findings curated in the GWAS 
catalogue67, we find that the proportion of druggable genes 
present in regions of LD with disease-associated SNPs is an 
approximately constant proportion of all genes present in 
such regions, that this is consistent across disease 
categories, and close to the proportion of druggable genes in 
the genome overall (i.e. ~4000/20,000 = 0.2). This would 
be expected if disease association and druggability were 
independent.  However, others have found an apparent 
enrichment of druggable genes among disease-associated 
loci 73.  We expect this uncertainty will be resolved as more 
GWAS are undertaken in a wider range of diseases with the 
purpose of drug target identification and validation.  
 
Assumption 9: Inaccurate target selection is the exclusive 
reason for clinical phase (stage 2) drug development failure   
 
Drug development can fail for numerous reasons including 
idiosyncratic compound toxicity, incorrect dosing, 
unfavourable pharmacokinetics, incorrect end-point 
selection, mechanism-based adverse effects and commercial 
considerations. Nevertheless, recent reviews have 
documented lack of efficacy (despite adequate target 
engagement) as the reason for clinical phase drug 
development failures in around two-thirds of cases 24 25 28.  
With this asssumption, we will have over attributed failure 
due to inaccurate drug target selection. However, 
adjustment of the relevant estimates by the multiplication 
factor of 2/3 (to account for other reasons for failure) 
would not overturn our broad conclusions, given the orders 
of magnitude improvement in developmental success rates 
predicted from the genomic approach.  
 
Parameters 
We estimated several key parameters when making our 
calculations. Here we review their likely accuracy. 
 
Number of human protein-coding genes: As summarized in 
Box 4, recent estimates of the number of protein coding 
genes, derived from diverse sources of evidence, have 
settled to a figure of close to 20,000.  
 
Number of complex diseases: We recognize that it is 
problematic to define diseases based on the use of coding 
schemes such as ICD-10114, utilized primarily for billing 
and record keeping, which offer a finite list of possible 
disease options, and which classify disease mainly 
according to appearance rather than cause. We also 
recognize that an ultimate outcome of research on the 
genetic basis of human disease may be the reclassification 
of disease according to molecular mechanism rather than 
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appearance.  As diseases often lie on a spectrum, with 
overlaps in both disease phenotypes and genetic causation, 
defining discrete disease entities often involves a degree of 
subjectivity. In the post-genomic era, biomedical ontologies 
have been created to provide controlled terms for biological 
attributes. The emphasis of coverage in the Human 
Phenotype Ontology (HPO) is on phenotypic abnormalities 
and clinical observations rather than diseases, while the 
Experimental Factor Ontology (EFO) describes 
experimental variables from the cellular to disease level in 
the European Bioinformatics Institute (EBI) databases. The 
Human Disease Ontology (DO) is a biomedical resource of 
standardised disease concepts organised by disease 
aetiology.  It addresses the complexity of disease 
nomenclature through extensive cross mapping and 
integration of ICD, Online Mendelian Inheritance in Man 
(OMIM), Orphanet, EFO, National Cancer Institute (NCI) 
Thesaurus, SNOMED CT and MeSH concepts115 116.  As of 
20 January 2016, the DO had 9,196 terms. The number of 
terms in the DO is regularly updated with technical and 
conceptual advances in disease phenotyping and will 
increase with improved understanding of molecular 
pathways. Therefore, given the current state of knowledge, 
we propose that a figure of 10,000 is a reasonable estimate 
of the number of common human diseases with genetic 
susceptibility. However, we explain in earlier sections why 
the various probabilities we have estimated do not depend 
on the absolute number of disease entities under 
consideration. 
 
Number of susceptibility genes for common diseases: 
Estimating a reasonable figure for the number of 
susceptibility genes for common diseases is a critical 
parameter when estimating probabilities of drug 
development success and requires consideration of the 
genetic architecture of these conditions 54 55 117 118 119. This 
area is controversial, as reviewed by Gibson120, and recently 
by Pritchard54.  The approach we took in this article 
implicitly accepts the front-running, common-variant, 
common-disease hypothesis, which states that complex 
diseases and associated biological traits are determined by 
the additive (perhaps occasionally synergistic) action of 
common, small effect variants in a large number of human 
genes. Under this model, every individual carries a different 
repertoire of largely independently inherited variants. (This 
model also has implications for the success or otherwise of 
precision medicine therapies). 
 
The diametrically opposed hypothesis is that the association 
of multiple SNPs at any locus with a disease or trait seen in 
GWAS occurs exclusively because common SNPs mark the 
presence of unobserved, rare (large effect) variants present 
in subsets of the population (a phenomenon referred to as 
‘synthetic association’)121.  Rare variants of this type are 
under-represented in the commonly used genotyping arrays 
used in GWAS, may be difficult to impute from haplotype 
reference panels, and should be better captured by exome or 
whole genome sequencing.    
 
However, evidence from post GWAS fine mapping studies, 
and a recent report on the genetic architecture of type 2 
diabetes, in which whole genome sequencing allowed an 
unbiased survey of both common and rare variant effects in 
tandem, continues to provide evidence for the common 
variant common disease hypothesis122 123 124.  However, it is 
also clear that rare, or infrequent, large effect, coding 
variants can also coexist in any given gene. Evidence from 
GWAS and emerging sequencing studies also suggest that a 
very large number of loci contribute to susceptibility to 
most common diseases and biomedical traits, but that the 
sometimes hundreds of loci exerting the largest effect, 
detected most readily by GWAS, explain only a small 
fraction of the heritability, with the remainder perhaps being 
distributed across the many thousands of remaining genes 
throughout the large expanse of the genome. This 
‘omnigenic’ could be inaccurately interpreted as ‘all genes 
contribute (equally) to all diseases’. However, effect sizes at 
loci beyond ‘core’ (or ‘critical’) genes may be beyond 
detection even by massive expansion in sample sizes120. 
Moreover, even allowing for development of highly potent 
compounds against ‘peripheral’ targets, the biological effect 
may still be too small to be of therapeutic interest and might 
necessitate unfeasibly large clinical trials for any effect to 
be reliably detected. For this reason, we believe the concept 
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of scores or hundreds of causal (‘critical’, ‘core’) genes for 
any disease, i.e. those with the main effect, is still valid. 
 
We estimated the number of such genes for a given disease 
using information from published GWAS of common 
diseases with the largest available datasets. These have 
typically identified hundreds of genetic susceptibility loci.  
As it is conceivable that even more loci will be uncovered 
by further increases in sample size125, we also estimated 
relevant probabilities for 1000 ‘causal’ genes per disease 
(corresponding to around 200 druggable genes per disease).  
We consider a further 10-fold increase in the number of 
causal genes (to 10,000 genes per disease in total) is 
unlikely, if only because the observed rates of drug 
development failure from lack of efficacy would be difficult 
to explain if half of all genes in the genome (corresponding 
to 2000 of the 4000 druggable genes under Assumption 8) 
critically affected risk of any given disease.   
 
Size of the druggable genome: A historical perspective of 
the druggable genome was provided in Box 6.  We recently 
re-estimated the extent of the druggable genome based on 
up to date annotations of protein coding genes, information 
on protein motifs targeted by drugs that have been licensed 
since prior estimates of the druggable genome were made, 
and by incorporating predicted targets of monoclonal 
antibody therapeutics which are either membrane-bound or 
secreted proteins identifiable by specific motifs in their 
primary structure.  This estimate of approximately 4479 
druggable, protein-coding genes was used to inform the 
content of a new genotyping array developed specifically to 
facilitate genetic studies for drug target identification67.  
This figure was rounded (conservatively) to 4000 genes for 
the illustrative calculations used in the current paper.  We 
recognize this estimate is not fixed but likely to be revised 
with time as new therapeutic modalities are developed126, 
evidenced by recent clinical successes of RNA 
therapeutics127, of gene therapy128, and of gene editing 
technologies that may play a therapeutic role in certain rare 
disorders129.  However, we believe it is a reasonable first 
approximation that drugs that act by interfering with the 
action of proteins readily target only a subset of human gene 
products, and that the factors that determine whether a 
protein is druggable and whether it plays a controlling role 
in a disease are somewhat distinct.   This echoes the 
arguments made by others65, that the challenge in drug 
development is to identify the proteins that lie at the 
intersection of druggability and disease regulation, and that 
human genomics is in a unique position to delineate this set 




There are a number of limitations to our analysis. 
 
We have argued that cis-acting variation is widespread in 
the human genome, but it may not be universal.  In the 
absence of natural variation in a gene encoding a drug target 
of interest, influencing its expression or activity, it would be 
impossible to use the approach described to anticipate the 
pharmacological action of a corresponding drug. However, 
there may be ways of addressing this issue in the infrequent 
instances where this occurs. For example, in the absence of 
variants reliably influencing expression of the gene 
encoding interleukin-6, variants in the gene encoding the 
interleukin-6 receptor were used to model the effect of 
interference with interleukin-6 signaling on coronary heart 
disease risk, through pharmacological blockade of the 
receptor rather than the ligand105.  
 
Theoretically, since genetic influences on protein expression 
or activity are present from early life, they may entrain 
developmental adaptation (canalization) through changes in 
other pathways that mitigate any biologically adverse effect 
on the system as a whole66. Thus, the null association of 
variants in a gene encoding a drug target of interest in a 
particular disease need not completely exclude it as a 
therapeutic target. This is because drugs, particularly for 
common diseases, are administered late in life, when 
developmental adaptation is inactive. Yet there are now 
numerous instances of both common (small effect) and rare 
(large effect) variants in genes encoding druggable targets 
that reliably anticipate the effects of drugs for late life 
diseases (see Appendix 1). Thus, it would seem that 
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canalization is a more theoretical than practical 
consideration for genomic identification and validation of 
therapeutic targets. 
 
We have observed that cis-acting variants in a gene 
encoding a drug target can anticipate both the pattern and 
rank order of effects of the corresponding drug on disease 
biomarkers. However, the effect sizes observed, particularly 
with common genetic variants, are typically one fifth to 
tenth that of the cognate drug.  Thus, there remains the 
possibility that if certain biological actions are only 
observed beyond some threshold, achieved through target 
perturbation by a potent drug, but not by the weak effect of 
natural genetic variation, such variants will fail to anticipate 
the full spectrum of effects of drug treatment. Thus, any 
discrepancy in the effects of genetic variants and drug 
action might arise not only from off-target actions of a drug 
(not shared by natural genetic variation), but also because of 
on-target threshold effects. The availability of common 
(weak effect) and rare (large effect) genetic variants in the 
same gene, that allows the construction of an allelic series 
(effectively a genetic dose-response curve), may go some 
way toward mitigating this possibility in specific cases65 113.  
 
We noted previously that local correlation between SNPs 
(LD) might lead to ambiguity on the source of the 
association signal(s) at any locus.   Since LD can extend 
beyond gene boundaries, this issue can affect gene-centric 
as well as whole genome association studies, though 
perhaps less so. In such gene-centric studies, there remains 
the possibility that disease and biomarker associations 
attributed to the local gene of interest in fact arise from 
effects of adjacent genes.  Approaches for exploring and 
accounting for this possibility were discussed earlier. 
The genomic approach to target identification and validation 
we describe is also necessarily limited by the range of 
available phenotypes.  Failure to comprehensively capture 
phenotypes influenced by perturbation of the target of 
interest, could lead to incomplete anticipation of the effect 
of drug treatment.  Recently, the monoclonal antibody 
romosozumab targeting sclerostin for the treatment of 
osteoporosis was developed based on the observation that 
patients with rare mutations in the encoding gene have 
increased bone mass. This agent increased bone mineral 
density and reduced osteoporotic fracture rate in two phase 
3 randomised trials but, in one of the trials, the rate of 
serious adverse cardiovascular events was also increased130 
131.  Since prior genetic studies, which had focused mainly 
on patients with rare mutations, had not evaluated 
cardiovascular end-points, it remains uncertain whether the 
apparent adverse signal of cardiovascular safety is real and 
if so, whether it is an on- or off-target, or threshold effect.   
 
Finally, most common disease genetic association studies 
that might inform drug development that have been 
performed to date have been undertaken in population-based 
longitudinal cohorts or case-control control datasets, where 
cases typically represent the first occurrence of a condition 
(e.g. a coronary heart disease event). However, first-in-class 
agents for CHD, and for many other common conditions, 
are tested or used initially patients with established disease, 
for prevention of disease progression or recurrence132. 
Mendelian randomization studies for target identification 
and validation in longitudinal clinical cohorts with 
established disease are few, currently limited by the 
available datasets, and also perhaps by potential biases 
arising from survivorship of, or indexing by, an initial event, 
that may limit inferences that can be drawn133. Nevertheless, 
the rediscovery by GWAS of over 70 drug targets suggests 
that genes influencing disease onset can, in many (but 
perhaps not all) cases, provide useful insight on targetable 
pathways for prevention of progression or recurrence of 
common conditions. 
 
In our a priori and a posteriori calculations of 𝛾𝑝𝑐 and other 
relevant metrics, we artificially reduced drug development 
to two steps:  a preclinical component to predict target-
disease pairings destined for clinical phase success (stage 
1), and a clinical component (stage 2) to evaluate target-
disease pairings brought forward from stage 1. The 
approach allowed the generation of formulas that highlight 
the key variables influencing drug development success, and 
some estimates of their values, based on observed success 
rates. These calculations should be viewed as no more than 
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an illustration to help inform developers of the key variables 
influencing success rates. 
 
Part 4: Summary and implications for drug 
development 
 
“Knowing is not enough; we must apply. Willing is not 
enough; we must do.”  
 





Three crucial factors have conspired to inhibit drug 
development success:  
 
(a) The apparently widespread contamination of the 
scientific literature by false discoveries, which undermines 
the validity of the hypotheses used to prioritise the selection 
of drug targets for different diseases;  
 
(b) The poor predictive accuracy of orthodox preclinical 
studies, arising due to animal-human differences in 
pathophysiology; and  
 
(c) The system flaw in drug development that sees the 
definitive target validation step (the RCT) deferred to the 
end of the drug development pipeline.   
 
With reasonable assumptions about the number of protein 
coding genes, druggable proteins and human diseases, and 
using probabilistic reasoning, we estimated that the 











) of correctly selecting a causal, 
druggable protein-disease pair through a random pick from 
a sample space defined by the 4,000 genes that are 
predicted to encode druggable targets and 10,000 diseases, 
assuming an average of 100 causal genes per disease.  With 
a target success rate of  
2
100
, based on the orthodox (non-
genomic) approach to target selection and validation, over 
100 independent drug development programmes for each 
disease need to proceed in parallel to have a 90% 
probability of even one success.  
 
Based on reported clinical and preclinical success rates, and 
making reasonable assumptions about values of clinical 
phase type 1 and type 2 error rates (𝛼𝑐  and 𝛽𝑐), we also 
found evidence that the proportion of true target disease 
relationships studied in preclinical development is small, 
that these form only the minor proportion of nominally 
positive findings that are brought forward into clinical phase 
studies.  This likely contributes to the high preclinical false 
discovery rate and low clinical phase success rate. 
 
Even applying the assumption that the probability of a 
protein influencing the pathogenesis of one disease is 
independent of the probability of it influencing any other, 
we show that it is highly likely that even small groups of 
diseases taken at random share at least one common target.  
This implies numerous opportunities should exist for 
therapeutic repurposing, but also that even highly specific 
modification of any target still runs a high risk of 
mechanism-based adverse effects.  However, knowledge of 
the effect of target-specific perturbation on multiple disease 
outcomes currently remains incomplete because the 
orthodox approach to target identification and validation is 
neither systematic nor comprehensive. 
 
In contrast to established non-genomic, approaches to 
preclinical drug development, GWAS deliver a methodical 
and reliable means of specifying the correct drug targets for 
a disease, provided that the genotyping arrays that are 
deployed have sufficient coverage of the druggable genome, 
and that the studies are adequately powered.  GWAS differ 
from established non-genomic preclinical experiments for 
target identification in that the evidence source is the human 
not an animal model; the false positive (type 1) error rate is 
low (typically set at 5 × 10−8); every potential drug target 
is interrogated in parallel (not just a selected subset); and the 
study design shares features of an RCT, the pivotal step in 
drug development.  For these reasons, we suggest that 
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genetic studies will soon be universally regarded as an 
indispensable, though not exclusive element of drug 
development for common diseases.  By improving the 
efficiency and reliability of target identification, GWAS and 
similar genetic study designs offer the potential to overturn 
the currently poor odds of success currently beleaguering 
drug development.   
 
However, GWAS have yet to be optimally designed or 
sufficiently widely deployed to fully realise their potential 
to uncover the correct drug targets for many poorly treated 
diseases.  There are several reasons for this that relate to the 
design of genotyping arrays used in GWAS, the range of 
diseases studied, and the datasets used.   
 
Design of genotyping arrays used in GWAS:  Genotyping 
arrays used in GWAS to date have been designed to provide 
broad coverage of the human genome, while other widely 
used genotyping arrays were designed to fine-map disease-
associated loci identified by prior GWAS.  Neither design 
focuses explicitly on genes encoding druggable targets.  In 
whole genome arrays, local coverage of variants in genes 
encoding druggable targets could be sparse, while in fine-
mapping arrays such coverage could be incomplete.  For 
this reason, we recently specified the content of the Illumina 
DrugDev consortium genotyping array that combines the 
properties of a whole genome array with focal coverage of 
variants in the druggable genome to support genetic 
association studies for drug target selection and validation 
(‘druggable GWAS’) 67.  
 
Diseases represented in GWAS:  The 400 or so unique 
diseases and biomarkers subjected to GWAS so far 
represents only a fraction of the thousands of terms listed by 
disease classification systems or ontologies, or that are 
observed in electronic health record datasets. Moreover, 
retrospective power calculations suggest that sample sizes in 
many GWAS to date may have been insufficient to detect 
all causal, druggable targets.  Despite this, more than 70 of 
the 680 or so known drug targets have already been 
‘rediscovered’ based on therapeutic indications or 
mechanism-based adverse effects, signposting the future 
potential of this approach in drug development.   
 
Datasets used in GWAS:  Datasets subjected to GWAS up to 
now have typically been conducted one disease at a time. 
Yet, when information from such studies is collated, it 
becomes apparent that the same loci, genes or even SNPs 
can contribute to the susceptibility to more than one 
disorder, a phenomenon referred to by geneticists as 
‘pleiotropy’.  Pleiotropy can arise through a number of 
mechanisms83, but an important one for drug development is 
the involvement of the same encoded protein in the 
pathogenesis of more than one disease, flagging potential 
opportunities to repurpose therapies effective in one disease 
for another.  In this paper, we estimated that a single gene 
(and thereby a single druggable target) could affect the risk 
of 50 different disease entities. Undertaking GWAS one 
disease at a time and cross-referencing findings later is a 
relatively inefficient method for pleiotropy detection.  An 
alternative approach to pleiotropy detection at druggable 
targets is to undertake phenome wide association studies 
(PheWAS) using extremely large prospective cohorts, or 
genomic studies within healthcare systems. Though there is 
emerging activity in this area, there is much yet untapped 
potential.  
 
Implications for future drug development 
 
The concepts and calculations in this paper suggest avenues 
by which drug target selection and validation, and hence 
drug development success, might be improved in the future, 
even if a complete reversal of the odds of drug development 
success is only a theoretical rather than practically 
achievable goal.  
 
First, more systematic mining should be undertaken of data 
emerging from GWAS for the purposes of drug target 
identification.  Several groups, including our own, have 
initiated such work67 and new initiatives such as MR Base134 
and Open Targets135, and commercial spinouts (e.g. 
Genomics PLC) suggest there is a growing interest in this 
area. 
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Second, more systematic and comprehensive genomic 
studies of high priority targets could be undertaken 
prospectively against as broad a range of biomarkers and 
disease end-points as possible (drug-target PheWAS) to 
facilitate drug target validation. 
 
Third, to realise the full potential of genomics for both drug 
target identification and validation, genomic studies with 
comprehensive coverage of variation in the druggable 
genome need to be conducted at even larger scale, and with 
attention to multipe (not just single) biomarker and disease 
outcomes - joint genome- and phenome-wide association 
analyses (Figure 7).  This ‘big data’ approach requires 
resources that couple comprehensive genomics with 
extensive phenotype and disease capture.  One route to 
achieving this is to pull together analyses across cohorts, 
consortia and large national biobanks, and there are 
emerging examples of this approach136.  Cohort consortia 
and large national biobanks can also exploit their ability to 
undertake and evaluate emerging technologies in detail (e.g. 
transcriptomics, epigenomic, proteomic and metabolomic 
measures in tissues, blood and urine).  Summary level 
genetic associations with mRNA and protein expression, 
with metabolite level and with disease risk obtained in 
different datasets can subsequently be connected by a 
variety of statistical methods, to elucidate pathways to 
disease, because natural genetic variation (unaffected by 
disease and allocated at random) provides a fixed anchor 
point with which to connect such datasets, exploiting the 
central dogma137 of the unidirectional flow of information 
from DNA to RNA, to protein and via downstream 
mechanisms to disease.  It should be possible in this way to 
gain comprehensive insight on mechanism and pathway, as 
well as the likely downstream consequence of targeting a 
druggable protein pharmacologically. 
 
However, we believe a further step to increase the scale, 
breadth and depth of the approach is to embed genomic 
analysis within the healthcare setting so that information on 
natural genetic variation could be linked to the multiplicity 
of clinical and disease outcome data ascertained during 
routine clinical care138. 
 
To achieve a shift in development of this type, the benefits 
need to be clear to healthcare providers (whether insurers or 
governments), to academia and industry and, most 
importantly of all, to patients and society, addressing 
legitimate concerns that might exist about privacy, security 
and secondary use of health data.  
 
If such concerns can be addressed, through rigorous 
governance and data security, a new model of drug 
development might supervene because healthcare data 
typically resides outside the domain of the pharmaceutical 
industry within the healthcare sector, which, in some 
countries, is wholly or substantially state-run.   
 
In turn, this would dictate that a new funding and delivery 
structure might need to be established, at least for the 
component of drug development that relates to target 
identification and validation.  
 
We explore these issues in greater detail. 
 
Healthcare genomics as a means to increase the scale and 
range of gene-disease associations to improve drug target 
identification:  Most datasets used in prior GWAS have 
either been investigator-led collections of patients with 
single diseases or population based cohort studies.  Efforts 
to expand existing studies or to make new disease 
collections proceed sporadically because they are expensive 
to undertake and unattractive to research funders given that 
the initial creation of the dataset, no specific scientific 
hypothesis is explored.  Population cohort studies measure 
numerous preclinical biomarkers and are increasingly being 
enriched with new proteomic and metabolomics measures.  
However, only relatively modest numbers of cases of 
different disorders accumulate in such datasets over time, 
determined by their natural incidence rates. Consortia of 
cohort studies, and large national biobanks139 have gone 
some way towards achieving the necessary scale but we 
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believe a further step-change is now needed to maximise the 
value of genetic studies for drug target identification.   
 
Based on the arguments developed in this paper, we propose 
that genotyping or eventually sequencing be embedded in 
routine healthcare settings to explicitly aid target 
identification and validation for drug development.  This is 
because routine diagnostic and prognostic tests are 
undertaken, and clinical diagnoses made in patients (as well 
as healthy citizens as part of preventative medicine efforts) 
on a scale and with a range that would be challenging to 
reproduce using investigator-led case collection or cohort 
studies in the conventional research setting.  Indeed, in 
countries with healthcare systems that provide universal 
coverage such as the National Health Service in the UK, the 
theoretical cohort size extends to the whole population (63 
million people in this example), which would encompass 
disease collections of unsurpassed size and breadth. Were 
such healthcare datasets to be connected to information on 
genetic variation, even at summary level, the genotype-
disease associations that would be gathered would enable 
drug targets to be matched accurately, systematically and 
efficiently to the multiplicity of diseases occurring in such 
healthcare settings, with the bonus of capturing multiple 
disease outcomes in the same individual. 
 
There are already precedents to using healthcare data at this 
scale for research.  In the UK, the Clinical Practice Data 
Link140 has provided anonymised primary care records for 
research since 1987 and, more recently, CALIBER141 has 
created a research cohort of ~10 million individuals by 
linking health records from primary care, hospital episodes, 
disease registry and mortality statistics.  Mature efforts to 
utilise routine healthcare data for research have also been 
established in Scandinavia and elsewhere142.  In the USA, 
precedents have already been set for connecting genotyping 
data to healthcare records to help identify disease-
susceptibility and treatment response genes, e.g. in the 
EMERGE consortium143 and the Million Veterans 
Programme144. In the UK, information on genome sequence 
is being connected to health record data in UK Biobank, in 
patients with rare diseases through the Genomics England 
(GEL) project145 and in individuals from ethnic minority 
groups with a high prevalence of certain diseases and a high 
degree of relatedness through the East London Genes and 
Health Initiative146.   
 
A national healthcare genomics effort would build on and 
complement these efforts. It would extend research 
platforms based on electronic health records alone (e.g. 
CPRD and CALIBER) into the genomic space. It would 
surpass the scale and representativeness of existing 
genomics healthcare platforms or initiatives (e.g. EMERGE 
or Geisinger, which have been in the vanguard of these 
developments, but which are confined to participating 
private healthcare systems) as well as the Million Veterans 
Programme which, through its design, includes almost 
exclusively male participants (see Table 6 for other 
examples of genomics and healthcare initiatives).  
Moreover, unlike GEL and the East London Genes and 
Health project, where recruitment is highly targeted, a 
national genomics effort would receive all comers. Until 
costs fall further and informatics pipelines are more 
streamlined, it could also focus on genotyping using fixed 
content arrays, exploiting increases in the number of 
genotyping assays per array and improved reference panels 
for imputation.  This approach would be less expensive and 
less analytically demanding than whole-genome or whole-
exome sequencing.  As sequencing eventually becomes 
more cost-efficient this technology would eventually replace 
genotyping. 
 
The optimal mechanisms for obtaining consent, for bio-
specimen collection, and for data management would need 
to be established, but much could be learnt from pre-
existing efforts. For example, bio-specimen collection might 
occur in hospital (at the point of emergency or elective care, 
during imaging or blood taking), in primary care, and / or by 
a direct-to-patient approach, using a despatched saliva 
collection kit, or some combination.  
 
Justifying a healthcare genomics initiative to healthcare 
providers and users:  The full engagement, understanding 
and support of patients and healthcare providers would need 
.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
37 
 
to be gathered at scale, with an open dialogue about the 
potential risks (e.g. of unintended patient data disclosure) 
balanced against individual and societal benefits.   Recent 
enterprises such as the Transforming Genetic Medicine 
Initiative (TGMI)147, the Personal Genome Project148 and 
Patients Like Me149 may have an important role to play, if 
the ideas are to gain traction. 
 
Healthcare providers and users might at first consider any 
potential research benefits from the initiative we describe to 
be too speculative and the benefits too remote.  However, 
we believe the arguments elaborated in this paper and 
elsewhere make the overall scientific and economic case 
compelling.  Moreover, evidence is already emerging that 
genomics has whet the public appetite for wider 
participation in medical research.   For example, direct to 
consumer genotyping has been available for some time 
through 23andme and other providers150, including 
distribution through high street outlets.  Participants 
submitting samples to 23andMe outside the UK have had 
the opportunity to participate in medical research by 
submitting self-reported healthcare data.  Such information 
has already contributed to disease gene discovery in 
Parkinson’s disease151, depression152 and a range of other 
diseases and traits153. Similar efforts are being made by the 
academia led Genes for Good collaboration154. It seems not 
a very great leap of faith to consider that, with appropriate 
public discourse on potential benefits, and mitigation of any 
risks, that there could be widespread public enthusiasm for 
an initiative that explicitly links anonymised personal 
genomic data to health records for the purpose of 
accelerating drug development, under a new model, to the 
benefit of society.  
 
Since healthcare providers and users might still rightly 
argue for more immediate and individual benefit from a 
healthcare genomics initiative, the genotyping arrays for this 
project could be designed with a dual purpose. Genotypic 
information of immediate value in healthcare decision-
making could be made available to patients and their 
doctors as part of a healthcare episode: personal healthcare 
genomics for diagnosis, risk assessment and individualised 
treatment.  This could include information on clinically 
actionable genetic variants that influence beneficial and 
adverse drug response, disease risk155, compatibility of 
transfusions and transplants, or risk of recessive genetic 
diseases that might manifest in future generations, to aid 
preconception planning, as such variants become 
sufficiently validated.  Validated genotypic information 
from prior GWAS of general interest to patients could also 
be returned, e.g. on ancestry; on genes influencing sleep 
pattern, facial appearance, hair and eye colour, coffee and 
alcohol metabolism and so on.  In parallel, the remaining 
genomic information from participants, linked anonymously 
to health record phenotypes and disease outcomes, would 
contribute in aggregate (at summary not individual level) to 
large-scale investigations of the causes of human diseases 
and the identification of disease-specific drug targets: public 
health genomics for drug development.   
 
Democratising drug development:  If accepted, an effort 
such as this would be likely to convert drug target 
identification and validation from an almost exclusively 
private sector, commercially sensitive enterprise to an open, 
pre-competitive, societal endeavour, with the joint 
involvement of academia and industry, healthcare providers 
and healthcare users, all with the shared goal of developing 
new medicines more efficiently.  In effect, drug 
development would become democratised; with healthcare 
users also becoming participants in drug target discovery 
and validation. 
 
If new medicines are to arise from this endeavour, there 
would still need to be intellectual property and revenue 
opportunities for commercial partners.  The biotech and e-
tech industries could be engaged to develop and deploy the 
optimal tools for bio-sample collection, genomic analysis, 
data generation, management and interpretation.   The 
pharmaceutical industry would continue to lead on the 
numerous, essential tasks of drug development beyond 
target selection and validation including compound 
synthesis and screening, detailed mechanistic studies to 
elucidate mode of action, toxicology, pharmacokinetics, 
first-in-man studies and clinical trials.  The intellectual 
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property and commercial advantage would accrue from the 
agents developed, and from developing and evaluating the 
best drugs most efficiently against targets that have already 
been reliably deduced and validated.  Since these activities 
would be concentrated on the correct therapeutic targets, 
and less likely misplaced, the risk of development failure 
should be reduced.  This should stimulate a shift in R&D 
from the derivative to innovative, inspiring drug 
development for diseases that have previously been 
considered too risky to tackle.  The benefits to society 
would come from containing drug development costs and 
expanding the therapeutic armamentarium against a broader 
range of diseases.   
 
There would be additional benefits from such an effort. We 
have focused here mainly on genomic studies for matching 
targets with diseases (target identification). However, in 
related work (see Appendix 1) we (and others) have shown 
that the principle can also be used to anticipate the spectrum 
of effects of pharmacological action on biomarkers, 
surrogate and clinically relevant disease end-points. 
Mendelian randomisation for drug target validation has 
been used to accurately predict phase 3 trial outcomes, 
distinguish on- from off- target effects of drugs, correctly 
identify detailed biomarker profiles of therapeutic 
response, and to identify repurposing opportunities for 
licensed therapies.  This underscores the view that such 
studies are not just useful for target identification but can 
also for inform drug development programmes from start to 
finish by indicating biomarkers of therapeutic response to 
measure in phase 1/2 clinical studies, and the relevant 
spectrum of clinical outcomes that should be ascertained in 
clinical trials. The incorporation of outcomes in clinical 
trials that are anticipated to be affected by pharmacological 
action on a particular target (target-specific outcomes of 
both efficacy and safety) would represent a departure from 
the current norm where end-points in a particular 
therapeutic area tend to be uniform regardless of the target 
being evaluated.  Genetic information could also be useful 
for compound optimisation since the profile of biomarker 
effects of a SNP in a gene encoding a drug target should be 
those of a clean drug with no off-target actions 84 104. Where 
compounds are developed that have actions that are distinct 
from those observed in a genetic study, these may be off-
target effects, and suggest that a more specific compound 
may need to be developed before the programme 
progresses.  By the same principle, PheWAS would inform 
which clinical efficacy and safety end-points should be 
specified as outcomes in RCTs of compounds against a 
specified target.  The spectrum of outcomes could differ 
from target to target, even for two targets being evaluated 
for the same primary disease indication. RCTs would need 
to be powered for both safety and efficacy outcomes, so that 
the balance between the benefits and any risk of target 
modification can be quantified before licensing.  This 
should reduce the problem of mechanism-based side effects 
only emerging post marketing.  This would also ensure that 
RCTs do not fail for failure to select the correct end-points, 
or because of the contamination of composite end-points 
(and thereby dilution of any treatment effect) by inclusion 
of outcomes that are unaffected by target modification. 
 
Delivery vehicle and funding:  The appropriate delivery 
vehicle for such an initiative requires careful consideration. 
It could be a form of social enterprise entrusted to create an 
open innovation platform where individual data is secured 
and protected, while aggregated data on genetic associations 
is shared, for the purpose of drug target identification and 
validation. Investment for the platform could come from a 
partnership of academic funders, healthcare and industrial 
sources with the knowledge generated helping all sectors 
and stakeholders.  
 
Patients and healthcare providers would benefit from more 
efficient drug development, cost containment and, as a 
wider range of diseases is tackled, from access to a wider 
range of therapies.  This could encourage government 
investment from healthcare, research, and business and 
innovation funding streams.   
 
The biotech and digital technology sectors would benefit 
from a growing market for their technologies, while the 
pharmaceutical sector would benefit from what we believe 
will be greatly reduced failure rates in drug development.  
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The societal benefits that we believe will accrue may also be 
attractive to entrepreneurs looking to invest in a 
transformative social enterprise.  
 
The leadership and oversight of such an endeavour would 
need to be trustworthy and accountable.  It could come as a 
natural progression for academic medical centres that have 
established strong translational research programmes.  In 
England, for example, these are funded by the National 
Institute of Health Research through Biomedical Research 
Centres (BRCs) formed of University / NHS partnerships, 
with the deep involvement of patients in their research 
activities.  Increasingly, such centres are also establishing 
collaborative research activities and partnerships with 
industry, based on projects that are most likely to have 
patient benefit.  Mature patient and public involvement 
activities, which underpin the work of all BRCs, could help 
identify and address patient and societal concerns, gauge 
enthusiasm for the proposal and, if accepted, help enrol 
patient champions for the project. Law Faculties in the 
academic sector, working with their counterparts in the 
healthcare systems and industry would also be well placed 
to develop solutions for legal, ethical and data protection 
issues that would undoubtedly arise. 
 
Whatever the organisational structure, the outputs of the 
project – information on the correct drug targets for human 
diseases, and the outcomes relevant to perturbation of 
individual targets – would be made available without 
restriction, using an open access model.  This would ensure 
target identification is pre-competitive, with any 
commercial advantage and intellectual property coming 
from other aspects of drug development. 
Conclusions 
 
The fundamental problem in contemporary drug 
development has been the unreliability of target 
identification leading to low development success rates, 
inefficiency and escalating cost to healthcare users.  
Genomics now provides a tool to address the problem 
directly by accurate identification of proteins that both play 
a controlling role in a disease and which are amenable to 
targeting by drugs.  Maximising the opportunities arising 
from this paradigm requires the wider use of genomics in 
the healthcare setting and with this, the active participation 
of healthcare users in drug development.  The 
democratisation of drug development could have the 
consequence of reducing wasted investment, increasing 
value for investors and, eventually, reducing drug price 
inflation for healthcare providers. It might also provide the 
sorely needed stimulus for true drug development 
innovation, to the benefit of patients, health systems, 
business and society.  
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Orthodox drug development Mendelian randomisation trials (MRT) 




Therapeutic area Outcomes assessed 
in preclinical studies 
or RCTs of selective 
drug interventions 
Findings from 
preclinical studies or 







Findings from MRTs Inferences drawn from 
comparison of the 
findings from preclinical 
studies or RCTs and MRT 
Cholesteryl ester 
transfer protein[1] 
Torcetrapib Phase III Cardiovascular 
disease 
Blood lipids (total-, 










Unintended increase in 
CVD events 
CETP[2] Blood lipids (total-, 




Associations with blood 
lipids consistent with 
effects in RCTs. No 
genetic association with 
BP. 
Blood pressure elevating effect 









Blood lipid fractions, 
weight, type 2 
diabetes risk 
Statin treatment in 
RCTs linked to 
increased weight and 
risk of type 2 diabetes. 
HMGCR[3] Blood lipid fractions, 
anthropometric 
measures, glucose 
and insulin, type 2 
diabetes risk 
HMGCR SNPs associated 
with lower LDL-C, 
higher weight, fasting 
glucose and insulin, and 
type 2 diabetes risk 
Increased risk of type 2 diabetes is 
an unintended on-target effect of 
statins mediated in part through 
weight gain 
Niemann-Pick C1-like 1 
[4] 














outcomes in patients 




Plasma lipid levels 
and risk of coronary 
heart disease. 
Inactivating mutations in 
NPC1L1 are associated 
with lower LDL-cholesterol 
and protection from 
myocardial infarction risk. 
Niemann-Pick C1-like 1 is a 
validated target for LDL-
cholesterol lowering and 
coronary heart disease 
prevention. 
Proprotein convertase 
subtilisin/kexin type 9 
serine protease [6] 
Alirocumab, 
evolocumab 













in patients with or at 





rosk of coronary heart 
disease 
Inactivating 
mutations in PCSK9 
associated with 
reduced LDL-
cholesterol and CHD 
risk 
Proprotein convertase 
subtilisin/kexin type 9 serine 
protease is a validated target 
for LDL-cholesterol lowering 
and reduction in 
cardiovascular risk 
Glucagon-like 
peptide-1 receptor [8] 









Liraglutide reduced risk 
of  death from 
cardiovascular causes, 
nonfatal myocardial 
infarction, or nonfatal 
stroke among patients 





glycaemic traits, lipids, 
blood pressure, risk of 
type 2 diabetes and 
coronary heart disease 
A low frequency, 
coding region 
missense variant in 
GLP1R is associated 
with lower fasting 
glucose, diabetes 
risk and risk of 
coronary heart 
disease. 
GLP1R is a validated target for 
treatment of diabetes and 
reducing coronary heart 
disease risk 
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in preclinical studies 
or RCTs of selective 
drug interventions 
Findings from 
preclinical studies or 






Findings from MRTs Inferences drawn from 
comparison of the 
findings from preclinical 






Darapladib Phase III Cardiovascular 
disease 
Major cardiovascular 
events or major 
coronary events 
No reduction in CVD 
events in patients 
with stable coronary 
disease or recent ACS; 
despite reductions in 







markers, and CHD 
events 
PLA2G7 variants were 
not associated with 
alterations in 
cardiovascular risk 
markers or CHD events 
Lp-PLA2 is not involved in the 
development of 
cardiovascular disease; low 




Tocilizumab Phase III Autoimmune 
disease 
Blood lipid fractions 
and inflammation 
markers including IL- 
6, CRP and 
fibrinogen 






characteristic of IL-6 
blockade 
IL6R[14] Blood lipid fractions 
and inflammation 
markers including iL-6, 
CRP and fibrinogen. 
Cardiovascular events 
including CHD events 
and abdominal aortic 
aneurysm 
Variants in the IL6R 
gene that recapitulate 
the biomarker profile of 
IL6-R blockade were 
associated with a 
reduction in CHD events 
IL-6 receptor signalling is 
involved in the 
development of CHD. The IL-6 
receptor blocker tocilizumab 
could be repurposed for the 









Effects of CRP on 
processes believed 
to contribute to 
atherosclerosis 
studied in vitro or in 
animals. 
Associations of CRP 




associations of CRP 
with CVD events in 
humans, but studies 
prone to confounding. 
Pro-atherogenic 
effect of CRP in vitro 
and in animals later 
proved to be 
artefactual. 
CRP[16] Inflammation and 
coagulation markers, 
blood lipid fractions, 
and coronary heart 
disease events 
SNPs in the CRP gene 
exclusively associated 
with CRP exhibited no 
association with CHD. 
No causal association of 
CRP with CHD based on 
instrumental variables 
analysis. 
CRP is not  
Causal in CHD pathogenesis; 
priority as a therapeutic target for 









markers, and CVD 
events 
No beneficial effect of 
varespladib on CVD 
events in patients 
with recent acute 
coronary syndrome 
(ACS), despite a drug- 
induced reduction in 
sPLA2 concentration 
and activity 
PLA2G2A[18] sPLA2 mass and 
activity and major 
vascular events (MVE) 
in general populations 
and patients with ACS 
SN s in the PLA2G2A 
gene were associated 
with substantial 
alterations in sPLA2 
mass and activity but not 
with MVE 
sPLA2 is not involved in the 
development of cardiovascular 
disease; dismissed as a 





channel 4 [19] 





Risk of atrial 
fibrillation 
Develop d for ngina 
and h art fail re, 
post-hoc  m ta-
alysis of RCTs 
(motivated by genetic 
findings [14, 15], 
indicated ivabridine 
treatment is 
associated with a 







Variants in the gene HCN4 
encoding the target of 
ivabridine associate with a 
higher risk of atrial 
fibrillation.   
Atrial fibrillation is a 
mechanism-based adverse 
effect of ivabridine treatment.  
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Appendix 1.  
Comparison of the findings from orthodox randomised controlled trials or meta-analyses, and Mendelian randomisation trials of the corresponding therapeutic target.







in preclinical studies 
or RCTs of selective 
drug interventions 
Findings from 
preclinical studies or 






Findings from MRTs Inferences drawn from 
comparison of the 
findings from preclinical 
studies or RCTs and MRT 
TNF receptor 1 and 

















Multiple sclerosis  A variant in the TNFRSF1A 
that encodes the TNF 
receptor 1 gene indices 
expression of a soluble 
form of TNFR1 that blocks 
the effect of TNF, and 
associates with a higher 
risk of MS. The mechanism 
mimics that of monoclonal 
antibodies against TNF.  
Exacerbation of MS induced by 
anti-TNF monoclonal antibodies 
is mechanism based. 
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Calculation of the probability of success for a company 
that initiates 𝑵 parallel pre-clinical trials but will only 
pursue one of the signals to a further clinical trial. 
 
Suppose industry selects 𝑁 targets at random from a pool of 
𝑡 targets where only 𝑐 targets are causal to the disease of 
interest. The 𝑁 pre-clinical programmes will generate a 
number of positive signals of which the company will select 
only to progress to clinical phase following which there will 
be a licensing success (if the signal comes from a true 
target) or failure if the preclinical signal is a false positive.  
To calculate the probability of eventual licensing success we 
consider a situation where many companies repeat an 
experiment involving 𝑁 preclinical programmes only 
pursuing only one of the positive signals to a phase 3 
clinical trial, and then calculating what proportion of such 
trials will result in a licensing success.   
 
1) We first calculate the probability of having 𝐴 causal 
targets among the 𝑁 targets selected at random from the 
pool of 𝑡 possible targets.  Each company will select a 
different number by chance (𝐴 =  0, 1, 2, 3 …) with the 

















So, if 𝑡 = 4000 with 𝑐 = 20, and we run 𝑁 = 20 pre-
clinical trials then: 
 
𝑃 (𝐴 = 0)  =  0.90 
𝑃 (𝐴 = 1)  =  0.09 
 
2) We next calculate the probability of generating true 
signals (𝑆𝑡) and false signals (Sf):  The 𝐴 causal targets 
in the 𝑁 programmes can generate from 0 to 𝐴 signals 
(𝑆𝑡 =  0, 1 …  𝐴), while the non-causal target can 
generate from 0 to 𝑁 − 𝐴 signals (𝑆𝑓 =  0, 1, 2 …  𝑁 −
𝐴). Each of these probabilities follow a binomial 
distribution independent from each other: 
 
𝑃 (𝑆𝑡) = (
𝐴
𝑆𝑡
) 𝛽𝐴−𝑆𝑡(1 − 𝛽)𝑆𝑡   
𝑃 (𝑆𝑓) = (
𝑁 − 𝐴
𝑆𝑓
) 𝛼𝑆𝑓(1 − 𝛼)𝑁−𝐴−𝑆𝑡  
 
Where (1 − 𝛽) and  are the probabilities that a causal 
and non-causal target will produce a signal 
respectively.   The two probabilities being independent, 
the probability of a particular combination of signals 
from causal and non-causal targets is the product of the 
separate probabilities: 𝑃(𝑆𝑡, 𝑆𝑓)  =  𝑃(𝑆𝑡) 𝑥 𝑃(𝑆𝑓). 
For example, the probability that, in a given repetition 
the causal targets produce 2 signals and the non-causal targets 
produce three signals is 𝑃(𝑆𝑡 = 2 , 𝑆𝑓 = 3)   =  𝑃(𝑆𝑡 = 2)  ×
 𝑃(𝑆𝑓 =  3) 
 
3) The probability of selecting a real target among a combination 
of true and false signals (𝑆𝑡, 𝑆𝑓) is given by the proportion of 
true signals: 𝑆𝑡 / (𝑆𝑡 +  𝑆𝑓) 
 
Thus, for a given 𝑁, 𝑐 and 𝑡, the final probability of licensing 
success across all possible values of 𝐴, 𝑆𝑡 and 𝑆𝑓 is: 
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Table 1a. The difference between the type 1 error (false-positive) rate (𝛼) and the false-discovery rate (𝐹𝐷𝑅). 1000 different hypotheses in a field are tested by 
experiments designed with a detection rate (power; 1 − 𝛽) = 0.8, with 𝛼 = 0.05. With 100 real effects to discover (𝛾 = 0.1), the false discovery rate is 45/125 =





































20 855 875 
  
Total 100 900 1000 
  
Outcome Causal pairings Non-causal pairings Hypotheses tested 𝑻𝑫𝑹 𝑭𝑫𝑹 
Declared positive 𝛾(1 − 𝛽) 𝛼(1 − 𝛾) [𝛾(1 − 𝛽)] + [𝛼(1 − 𝛾)] 
𝛾(1 − 𝛽)
𝛾(1 − 𝛽)  +  𝛼 (1 − 𝛾)
 
 𝛼(1 − 𝛾) 
(1 − 𝛽) 𝛾 +  𝛼 (1 − 𝛾)
 
Declared negative 𝛾𝛽 (1 − 𝛼)(1 − 𝛾) [𝛾𝛽] + [(1 − 𝛼)(1 − 𝛾)] 
 
 
  𝛾 1 − 𝛾 1   
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Table 2: A priori estimates of preclinical (pc), clinical (c) and overall (o) drug development success contrasting orthodox (non-genomic) with genomic approaches. 𝑇𝐷𝑅, 𝐹𝐷𝑅,   







⁄  ) when the sample space is defined by a) 𝑁𝐺 ×  𝑁𝐷, and b) when the sample space is restricted to the druggable genome (𝑁𝐺 ×  𝑁𝑇). See text for details. 
 
 
a             
𝐶̅ 𝛾𝑝𝑐  𝛼𝑝𝑐  𝛽𝑝𝑐   𝐹𝐷𝑅𝑝𝑐  𝑆𝑝𝑐  𝑇𝐷𝑅𝑝𝑐 =  𝛾𝑐  𝛼𝑐  𝛽𝑐  𝐹𝐷𝑅𝑐  𝑇𝐷𝑅𝑐 𝑆𝑐  𝑆𝑜 
10 0.0001 0.05 0.2 0.9984024 0.05008 0.0015976 0.05 0.2 0.97503657 0.02496343 0.051198203 0.00256 
100 0.001 0.05 0.2 0.98423645 0.05075 0.01576355 0.05 0.2 0.79601594 0.20398406 0.06182266 0.00314 
1000 0.01 0.05 0.2 0.86086957 0.0575 0.13913043 0.05 0.2 0.27887324 0.72112676 0.154347826 0.00888 
10 0.0001 0.00000005 0.2 0.00062455 0.00008 0.99937545 0.05 0.2 0.000039057 0.99996094 0.79953159 0.000064 
100 0.001 0.00000005 0.2 0.000062434 0.0008 0.99993757 0.05 0.2 3.9023E-06 0.9999961 0.799953175 0.00064 
1000 0.01 0.00000005 0.2 6.1875E-06 0.008 0.99999381 0.05 0.2 3.8672E-07 0.99999961 0.799995359 0.0064 
             
b             
𝐶̅ 𝛾𝑝𝑐  𝛼𝑝𝑐  𝛽𝑝𝑐   𝐹𝐷𝑅𝑝𝑐  𝑆𝑝𝑐  𝑇𝐷𝑅𝑝𝑐 =  𝛾𝑐  𝛼𝑐  𝛽𝑐  𝐹𝐷𝑅𝑐  𝑇𝐷𝑅𝑐 𝑆𝑐  𝑆𝑜 
10 0.0005 0.05 0.2 0.99205955 0.050375 0.00794045 0.05 0.2 0.8864745 0.1135255 0.055955335 0.00282 
100 0.005 0.05 0.2 0.9255814 0.05375 0.074418605 0.05 0.2 0.43736264 0.56263736 0.105813953 0.00569 
1000 0.05 0.05 0.2 0.54285714 0.0875 0.45714286 0.05 0.2 0.06909091 0.93090909 0.392857143 0.03438 
10 0.0005 0.00000005 0.2 0.00012492 0.00040005 0.99987508 0.05 0.2 7.8085E-06 0.99999219 0.799906309 0.00032 
100 0.005 0.00000005 0.2 0.000012437 0.00400005 0.99998756 0.05 0.2 7.7734E-07 0.99999922 0.799990672 0.0032 
1000 0.05 0.00000005 0.2 0.000001875 0.04000008 0.99999881 0.05 0.2 7.4219E-08 0.99999993 0.799999109 0.032 
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SNOMED CT Clinical 
Terminology 
422,382 https://www.nlm.nih.gov/research/umls/licensedcontent/snomedctfiles.html 
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Table 4 (following pages). Illustrative examples of mapping SNPs curated in the GWAS catalogue to genomic linkage dis-equilibrium (LD) intervals containing targets of 
licensed and clinically used drugs (adapted with modification from Finan et al. http://biorxiv.org/content/early/2016/07/26/066027). The gene encoding the drug target is listed 
using Human Genome Nomenclature Catalogue designation. Drug names and indications are from First Data bank. GWAS SNPs are listed according to Refseq number and 
physical distances are in base pairs (bp). Curation code refers to the correspondence between the treatment indication and GW AS disease or trait association (see Text). 
Examples are shown of treatment indication rediscoveries which refer to a drug target indication-genetic association match (Curation code 1= precise match, code 2=disease 
area match). For many of these the drug target gene is the sole occupant of the LD interval defined by the GWAS SNP. Examples come from a variety of disease areas and, 
for some diseases (e.g. type 2 diabetes and rheumatoid arthritis), multiple target rediscoveries are noted.  Examples of rediscoveries of mechanism of action (curation code 3) 
and mechanism-based side effects are also seen (curation code 4) 
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genes in LD 
interval 
ALDH2 DISULFIRAM Small molecule 1 alcohol drinking | 
drinking behavior 








6016 - 790230 1 -18 22 - 33 2 - 4 
PDE4D AMINOPHYLLINE Small molecule 1 asthma Acute asthma | Acute exacerbation of chronic 
obstructive airways disease | Bronchial 
asthma | Chronic obstructive pulmonary 
disease | Left ventricular failure - cardiac 
failure - cardiac asthma | Reversible airways 
obstruction | Routine maintenance therapy in 
chronic bronchitis and asthma  
rs1588265 19426955 448153 1 2 1 
IGF1R MECASERMIN Protein 1 body height Growth failure due to primary IGF-1 deficiency rs2871865 20881960| 
25429064 
2696 1 2 1 
TNFSF11 DENOSUMAB Antibody 1 bone density Prevention of skeletal related events in 
advanced malignancy involving bone | 
Treatment of bone loss associated with 
hormone ablation in prostate cancer | 
Treatment of osteoporosis in postmenopausal 
women to prevent fractures 
rs17536328| 
rs9525638 
24945404 6157 - 8295 1 1 1 








9531 - 63713 1 - 2 2 1 
PLG ALTEPLASE Enzyme 1 coronary heart 
disease | large 
artery stroke | 
stroke 
Acute ischaemic stroke: fibrinolytic 
treatment| Thrombolysis in acute myocardial 
infarction| Thrombolysis of occluded central 
venous access devices | Thrombolytic 
treatment in acute massive pulmonary 
embolism 
rs10455872 24262325 113152 3 3 2 
TNF ADALIMUMAB Antibody 1 Crohn's disease Active polyarticular juvenile chronic arthritis-
inadequate response to MTX | Active 
progressive rheumatoid arthritis | Moderate 
to severe plaque psoriasis: when other 
treatment is inappropriate | Moderate/severe 
ulcerative colitis: when other treatment is 
inappropriate | Rheumatoid arthritis when 
inadequate response to DMARDs incl. 
methotrexate | Severe active rheumatoid 
arthritis | Severe ankylosing spondylitis in 
adults if conventional therapy inadequate | 
Treatment of active & progressive psoriatic 
arthritis when DMARD inadequate | 
Treatment of active Crohn's disease 
rs1799964 21102463 1036 2 13 4 
CACNA1D AMLODIPINE Small molecule 1 diastolic blood 
pressure 
Essential hypertension when stabilised on 
same ingreds.in same proportions | 
Hypertension-not adequately controlled by 
individual components | Prinzmetal's angina | 
Prophylaxis of chronic stable angina pectoris | 
Treatment of essential hypertension |  
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genes in LD 
interval 
NPC1L1 EZETIMIBE Small molecule 1 LDL cholesterol | low 
density lipoprotein 
cholesterol 
measurement | total 
cholesterol 
measurement 
Combined hyperlipidaemia: lipid lowering 
therapy adjunct to diet | Homozygous familial 
hypercholesterolaemia (adjunct to statin 
therapy) | Homozygous familial 
hypercholesterolaemia: Adjunct to diet | 
Homozygous sitosterolaemia 
(phytosterolaemia) | Primary 
hypercholesterolaemia (hyperlipidaemia type 
IIa): Adjunct to diet | Primary 
hypercholesterolaemia: lipid lowering therapy 
adjunct to diet 
rs2072183 20686565| 
24097068 
1734 1 1 1 
PPARA GEMFIBROZIL Small molecule 1 LDL cholesterol | low 
density lipoprotein 
cholesterol 
measurement | total 
cholesterol 
measurement 
Mixed hyperlipidaemia when statin is 
contraindicated or not tolerated | Primary 
hypercholesterolaemia: lipid lowering therapy 
adjunct to diet | Reduction of cardiac events 
in hypercholesterolaemia | Severe 
hypertriglyceridaemia with or without low 
HDL cholesterol 
rs4253772 24097068 12050 1 7 2 
CASR CINACALCET 
HYDROCHLORIDE 
Small molecule 1 calcuim measurment Homoeopathic | Hypercalcaemia due to 
malignant disease | Hypercalcaemia in 
primary HPT when parathyroidectomy 
contraindicated | Secondary 







1585 - 12095 1 5 1 
IL6R TOCILIZUMAB Antibody 1 rheumatoid arthritis Active juvenile idiopathic arthritis (unresp to 
NSAIDs) in comb with MTX | Active juvenile 
idiopathic arthritis when inadequate response 
to NSAIDs | Rheumatoid arthritis (unresp to 
DMARD/TNF inhib.) in comb with 
methotrexate | Rheumatoid arthritis when 
inadequate response to DMARDs incl. 
methotrexate 
rs2228145 24390342 14956 1 1 1 
TNF ADALIMUMAB Antibody 1 rheumatoid arthritis Active polyarticular juvenile chronic arthritis-
inadequate response to MTX | Active 
progressive rheumatoid arthritis | Moderate 
to severe plaque psoriasis: when other 
treatment is inappropriate | Moderate/severe 
ulcerative colitis: when other treatment is 
inappropriate | Rheumatoid arthritis when 
inadequate response to DMARDs incl. 
methotrexate | Severe active rheumatoid 
arthritis | Severe ankylosing spondylitis in 
adults if conventional therapy inadequate | 
Treatment of active & progressive psoriatic 
arthritis when DMARD inadequate | 
Treatment of active Crohn's disease 
rs2596565 24532677 190015 24 145 27 
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GWAS EFO term 
 






















genes in LD 
interval 
ABCC8 GLIPIZIDE Small molecule 1 type II diabetes 
mellitus 
Non insulin dependent diabetes mellitus 
when diet has failed 
rs5219 19056611 4860 - 5802 3 5 3 
ABCC8 GLYBURIDE Small molecule 1 type II diabetes 
mellitus 
Type 2 diabetes (NIDDM) not controlled by 







4860 - 5802 3 5 3 
ABCC8 NATEGLINIDE Small molecule 1 type II diabetes 
mellitus 
Control of type-2 diabetes (NIDDM) with 
metformin if metformin inadequate 
rs5219 19056611 4860 - 5802 3 5 3 
ABCC8 REPAGLINIDE Small molecule 1 type II diabetes 
mellitus 
Control of type-2 diabetes (NIDDM) with 
metformin if metformin inadequate | Type 2 
diabetes (NIDDM) not controlled by 
diet,weight loss & exercise alone 
rs5219 19056611 4860 - 5802 3 5 3 
KCNJ11 GLIMEPIRIDE Small molecule 1 type II diabetes 
mellitus 
Type 2 diabetes (NIDDM) not controlled by 
diet,weight loss & exercise alone 
rs5219 19056611 1224 - 1306 1 5 3 
KCNJ11 GLIPIZIDE Small molecule 1 type II diabetes 
mellitus 
Non insulin dependent diabetes mellitus 
when diet has failed 
rs5219 19056611 1224 - 1306 1 5 3 
KCNJ11 GLYBURIDE Small molecule 1 type II diabetes 
mellitus 
Type 2 diabetes (NIDDM) not controlled by 







1224 - 1306 1 5 3 
KCNJ11 NATEGLINIDE Small molecule 1 type II diabetes 
mellitus 
Control of type-2 diabetes (NIDDM) with 
metformin if metformin inadequate 
rs5219 19056611 1224 - 1306 1 5 3 
KCNJ11 REPAGLINIDE Small molecule 1 type II diabetes 
mellitus 
Control of type-2 diabetes (NIDDM) with 
metformin if metformin inadequate | Type 2 
diabetes (NIDDM) not controlled by 
diet,weight loss & exercise alone 
rs5219 19056611 1224 - 1306 1 5 3 
PPARG PIOGLITAZONE 
HYDROCHLORIDE 
Small molecule 1 type II diabetes 
mellitus 
Combination treatment of Type 2 diabetes 
with insulin | Control of type-2 diabetes if 
metformin+sulphonylurea therapy is 
inadequate | Monotherapy for type2 diabetes 
if overweight and metformin inappropriate | 
Oral combination treatment of type 2 
diabetes  
rs1801282 24509480 64258 1 1 1 
SCN1A OXCARBAZEPINE Small molecule 1 Mesial temporal 
lobe epilepsy with 
hippocampal 
sclerosis | febrile 
seizures 
Epilepsy - combination of both partial and 
tonic-clonic seizures | Epilepsy - partial 
seizures  
rs7587026 24014518 5773 - 52194 1 3 1 
GRIN3B MEMANTINE 
HYDROCHLORIDE 
Small molecule 1 Alzheimers disease Moderate to severe Alzheimer's disease | No 
information available 
rs115550680 23571587 40689 8 8 2 






23999 - 108243 2 -3 2 -3 2 
SLC22A11 PROBENECID Small molecule 1 urate measurement 








6233 - 8364 1 1 - 2 1 - 2 
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GWAS EFO term 
 






















genes in LD 
interval 
SCN2A CARBAMAZEPINE Small molecule 2 febrile seizures Epilepsy - grand mal | Epilepsy - partial 
seizures | Epilepsy - tonic-clonic seizures | 
Prophylaxis of manic-depressive illness 
unresponsive to lithium | Trigeminal neuralgia 
rs3769955 25344690 14186 1 1 1 
DIO1 PROPYLTHIOURACIL Small molecule 3 thyroxine | 
thyroxine 
measurement 
Hyperthyroidism | Thyrotoxic crisis | 
Unlicensed product 
rs2235544 23408906 1189 1 4 1 
PDE4D DIPYRIDAMOLE Small molecule 4 asthma Alternative to exercise stress in thallium-201 
myocardial imaging | Ischemic stroke: 
Secondary prevention (with/without aspirin) | 
Secondary prevention of ischaemic stroke | 
Secondary prevention of transient ischaemic 
attacks | Thromboembolism+prosthetic heart 
valve: prophylaxis (+oral anticoagulant) | 
Transient ischemic attacks: Secondary 
prevention (with/without aspirin)  
rs1588265 19426955 448153 1 2 1 
ACHE RIVASTIGMINE Small molecule 4 resting heart rate Mild - moderate dementia in Alzheimer's 
disease | Mild - moderate dementia in 
idiopathic Parkinson's disease 
rs12666989 | 
rs314370 
20639392 861 - 34407 3 - 7 9 4 
ACHE NEOSTIGMINE 
METHYLSULFATE 
Small molecule 4 heart rate Myasthenia gravis | Paralytic ileus | 
Paroxysmal supra-ventricular 
tachyarrhythmias | Post operative distention| 
Post operative urinary retention | Reversal of 
residual competitive neuromuscular block | 
Unlicensed product 
rs13245899 23583979 861 - 34407 1 - 7l 9 4 
CHRM2 TOLTERODINE 
TARTRATE 
Small molecule 4 heart rate Symptomatic treatment of urinary urgency, 
frequency or urge incontinence 
rs2350782 23583979 62368 1 3 1 
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Table 6. Selected examples of Academia, Pharma, and Pharma-Academia initiatives concerning genomics and drug development 
 
 








Initiative Partners Drug development model Aims 
Accelerating Drug Development and Repurposing 
Incubator at Vanderbilt Universitya 
Multiple departments at Vanderbilt University 
Medical Centre 
Academic incubator De-identified genotype data linked to  de-
identified demographic and health record 
data to aid precision drug development 
and drug repurposing 
DECODE Geneticsb Decode is a subsidiary of Amgen, a 
biopharmaceutical company 
Within-company Discover genetic variation underlying 
human disease in the Icelandic population 
with the aim of diagnosing, treating and 
preventing disease 
Open Targetsc GSK, Biogen, European Bioinformatics Institute, 
Wellcome Trust Sanger Institute 
Pre-competitive, open access Public-private initiative based on the use of 
genomics for drug target validation  
Astra Zeneca 
Centre for Genomics Research 
Human Longevity, Inc 
Wellcome Trust Sanger Institute 
Institute for Molecular Medicine, Finland 
Within-company ‘Integrated genomics initiative to 
transform drug discovery and development 
across (AZ’s) entire therapeutic pipeline’ 
Eisai  
Andover Innovative Medicines Institutee 




‘Executing novel therapeutic targets 
validated by human genetics’ 
Regeneron Genetics Centref Geisinger Health System, 
and other health service and academic partners 
Within-company ‘Comparing genetic information against 
medical histories .to develop new means 
of diagnosing, preventing and/or treating 
medical conditions’ 
 
GSK-Regeneron UK Biobank Partnerhshipg GSK, Regeneron and UK Biobank Industry academia partnership, 
with 9 month exclusivity period 
for Pharma partners 
Exome sequencing of stored DNA from UK 
Biobank participants: 50,000 samples in 
year 1, 500,000 by year 3. 
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Figure 1. Sample space defined by 10,000 human diseases (columns) and 20,000 protein-
coding genes (rows).  Expanded region comprising 1/10,000𝑡ℎ of the whole sample space is 
enlarged: a (based on 10 causative genes per disease); b (based on 100 causative genes per 
disease); and c (based on 1000 causative genes per disease). Each cell represents a unique 
gene-disease pairing.  Dark blue cells indicate causal gene-disease pairings, light blue cells 






















.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
Drug development success and human genomics 
 57 
 



























.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 






































.CC-BY-NC-ND 4.0 International licensenot peer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was. http://dx.doi.org/10.1101/170142doi: bioRxiv preprint first posted online Jul. 30, 2017; 
Drug development success and human genomics 
 59 
 
Figure 2a. Venn diagram illustrating the probabilities of selecting a causal, druggable gene-
disease pair (𝐶𝐷 ∩  𝑇𝐷), a druggable gene disease pair (𝑇𝐷) and a causal, gene disease pair 
(𝐶𝐷) from a sample space of 200 𝑥 106 gene disease pairings, 100 causal genes per disease 
and 4000 druggable genes from the 20,000 in the genome. The dashed red circle encloses a 
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Figure 2b. Venn diagram illustrating the number of causal, druggable gene-disease 
pairs (𝐶𝐷 ∩  𝑇𝐷), druggable gene disease pairs (𝑇𝐷) and causal, gene disease pairs (CD) from 
a sample space of 200 𝑥 106 gene disease pairings, 100 causal genes per disease and 4000 
druggable genes from the 20,000 in the genome. The dashed red circle encloses a probability 
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Figure 3. Re-assorted ‘therapeutic genome’ of a hypothetical disease (𝑑1).  The 20,000 protein 
coding genes are organised into 100 causal and 19,900 non-causal genes. Causal genes are 
further subdivided into 20  that are also druggable and 80  that are not.  Of the 20 causal, 
druggable genes, 3 are the targets of licensed drugs for the treatment of 𝑑1. Of the non-causal 
genes, 3980 are druggable but not causal for 𝑑1.  The right hand panel indicates the expected 
number of true and false positive genes (including druggable genes) expected in a GWAS of 
𝑑1 undertaken with a sample size that provides power, 1 − 𝛽 =  0.8 and type 1 error rate of 𝛼 =
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Figure 4. Distribution of number of licensed drug compounds per target 
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Figure 5. Back calculation of proportion of true target-disease relationships (𝛾𝑝𝑐) studied in 
preclinical development, inferred from observed rates of clinical success (𝑆𝐶 = 0.1) and 
preclinical success (𝑆𝑝𝑐 = 0.4).  Estimates of 𝛾𝑝𝑐 assume power in clinical phase development 
 (1 − 𝛽𝑐 ) = 0.8 and false positive rate in clinical development, 𝛼𝑐 = 0.05, so that the 
proportion of true target-disease relationships in clinical development, 𝛾𝑐 = 0.0667. The graph 
shows estimates of 𝛾𝑝𝑐 (red line) for a range of values for power (1 − 𝛽𝑝𝑐 ) in preclinical 
development and corresponding estimates of the preclinical false positive rate, 𝛼𝑝𝑐 (blue line). 
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Figure 6. Probability of orthodox drug development success according to the number of 
candidate targets in the initial sampling frame (upper panel) and the number of parallel 
preclinical development programmes pursued (lower panel).  The calculations assume there 
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 Figure 7. Study designs relevant to drug target identification and validation based on human 
genomics: (a) conventional genome-wide association analysis in which variation in 20,000 
genes is tested against a single disease; (b) phenome wide association analysis of a gene 
encoding a drug target in which variation in a single druggable gene is evaluated against 
many (all) diseases; (c) druggable genome and phenome wide association analysis; and (d) 
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Supplementary tables 
 
Table S1.  Expected number of licensed drug targets rediscovered (𝑬𝑻) by 200 hypothetical 
GWAS of diseases with at least one licensed drug based on a range of plausible values of the 
power (1 − 𝛽) to detect each genetic locus encoding a licensed drug target, and a range of 
plausible values for the average number of licensed drug targets per disease.  (See text for 





Table S2. Effect of varying estimates of the number of causative genes per disease (𝐶), and 
the number of diseases (𝑵𝑫) on the probability of selecting a causal gene-disease pair (𝜸𝑪); 
the probability of selecting a causal, druggable, gene-disease pair (𝜸𝑪𝑻); and the number 













Number of licensed 
drug targets per disease 
Power 
(1 − 𝛽) 𝐸𝑇 (𝑆𝐷) 
1 0.6 120 (7) 
1 0.8 160 (6) 
1 0.9 180 (4) 
3 0.6 360 (12) 
3 0.8 480 (10) 
3 0.9 540 (7) 
5 0.6 600 (15) 
5 0.8 800 (13) 
5 0.9 900 (9) 
10 0.6 1200 (22) 
10 0.8 1600 (18) 
10 0.9 1800 (13) 
𝐶 𝑁𝐷  𝛾𝐶  𝛾𝐶𝑇 𝐸𝐷 
10 2500 0.0005 0.0001 1.25 
10 5000 0.0005 0.0001 2.5 
10 10000 0.0005 0.0001 5 
100 2500 0.005 0.001 12.5 
100 5000 0.005 0.001 25 
100 10000 0.005 0.001 50 
1000 2500 0.05 0.01 125 
1000 5000 0.05 0.01 250 
1000 10000 0.05 0.01 500 
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Table S3: Expected yield of causal druggable targets from orthodox (non-genomic) preclinical programmes according to the number of causal targets for each disease and 
whether the sampling frame is the whole genome or the druggable genome.    
 
 





 per disease 
Number of targets in 
sampling frame 




among all programmes 
Number causal 
druggable targets 
detected (1 − 𝛽 = 0.8) 
Number of non-
relevant targets 
declared positive (𝛼 =
0.05) 
10 20 20,000 0.01 (0.07) 0.008 0.49 
20 20 20,000 0.02 (0.1) 0.016 1.0 
50 20 20,000 0.05 (0.2) 0.04 2.5 
100 20 20,000 0.1 (0.2) 0.08 5.0 
200 20 20,000 0.2 (0.3) 0.16 10.0 
10 20 4,000 0.05 (0.2) 0.04 5.0 
20 20 4,000 0.1 (0.2) 0.08 1.0 
50 20 4,000 0.25 (0.4) 0.2 2.5 
100 20 4,000 0.5 (0.5) 0.4 5.0 
200 20 4,000 1 (0.7) 0.8 10.0 
10 200 20,000 0.1 (0.2) 0.08 0.5 
20 200 20,000 0.2 (0.3) 0.16 1.0 
50 200 20,000 0.5 (0.5) 0.4 2.5 
100 200 20,000 1 (0.7) 0.8 5.0 
200 200 20,000 2 (1) 1.6 10.0 
10 200 4,000 0.5 (0.5) 0.4 0.5 
20 200 4,000 1 (1) 0.8 1.0 
50 200 4,000 2.5 (1) 2 2.4 
100 200 4,000 5 (1) 4 4.8 
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Table S4. Number of drug development programmes (𝑁) that to be pursued in parallel to have 
a probability (𝑃) of at least one development success.  Analyses are based on either 90% or 
50% (evens) probability of at least one developmental success, and a range of development 
success rates (𝑝) starting with the currently observed industry wide average success rate of 
0.01  (See text for details) 
 
𝑃 (≥1 success) in N programmes 
Within-programme  
developmental success rate (𝑃𝑆) Number of parallel programmes (𝑁) 
0.9 0.01 229 
0.9 0.02 114 
0.9 0.1 22 
0.9 0.2 10 
0.9 0.5 3 
0.5 0.01 69 
0.5 0.02 34 
0.5 0.1 7 
0.5 0.2 3 
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Table S5. Expected number of true and false positives in parallel drug development programmes based on a sample of targets drawn from all or part of the 
druggable genome based on orthodox preclinical experiments designed with ( 1 − 𝛽) = 0.8 and 𝛼 = 0.05  (left hand panel).  Probability of eventual drug 

















false   
positives 

















of  a development 
success 
4000 20 20 0.08 1.00 2.9% 4.8% 33.1% 59.2% 5.0% 
2000 20 20 0.16 0.99 5.7% 9.2% 30.6% 54.5% 9.7% 
1000 20 20 0.32 0.98 10.6% 17.2% 26.0% 46.2% 18.3% 
200 20 20 1.60 0.90 33.3% 49.0% 6.5% 11.1% 60.4% 
4000 20 50 0.20 2.49 1.5% 16.8% 6.3% 75.5% 7.0% 
2000 20 50 0.40 2.48 2.7% 30.6% 5.2% 61.5% 13.3% 
1000 20 50 0.80 2.45 4.7% 51.4% 3.4% 40.5% 24.0% 
200 20 50 4.00 2.25 9.9% 89.1% 0.1% 0.9% 64.6% 
4000 20 200 0.80 9.95 0.0% 55.9% 0.0% 44.1% 7.5% 
2000 20 200 1.60 9.90 0.0% 81.2% 0.0% 18.7% 14.0% 
1000 20 200 3.20 9.80 0.0% 97.0% 0.0% 3.0% 24.8% 
200 20 200 16.00 9.00 0.0% 100.0% 0.0% 0.0% 64.7% 
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 Supplementary figures 
 
Figure S1a. Venn diagram illustrating the probabilities of selecting a causal, druggable gene-
disease pair (𝐶𝐷 ∩  𝑇𝐷) , a druggable gene disease pair (𝑇𝐷) and a causal, gene disease pair 
(𝐶𝐷) from a sample space of 200 𝑥 106 gene disease pairings, 1000 causal genes per disease 
and 4000 druggable genes from the 20,000 in the genome. The dashed red circle encloses a 
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Figure S1b. Venn diagram illustrating the number of causal, druggable gene-disease 
pairs (𝐶𝐷 ∩  𝑇𝐷), druggable gene disease pairs (𝑇𝐷) and causal gene disease pairs (𝐶𝐷) from 
a sample space of 200 𝑥 106 gene disease pairings, 1000 causal genes per disease and 4000 
druggable genes from the 20,000 in the genome. The dashed red circle encloses a probability 
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Figure S2a. Venn diagram illustrating the probabilities of selecting a causal, druggable gene-
disease pair (𝐶𝐷 ∩  𝑇𝐷), a druggable gene disease pair (𝑇𝐷) and a causal, gene disease pair 
(𝐶𝐷) from a sample space of 200 𝑥 106 gene disease pairings, 10 causal genes per disease 
and 4000 druggable genes from the 20,000 in the genome. The dashed red circle encloses a 
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Figure S2b. Venn diagram illustrating the number of causal, druggable gene-disease 
pairs (𝐶𝐷 ∩  𝑇𝐷) , druggable gene disease pairs (𝑇𝐷) and causal gene disease pairs (𝐶𝐷) from 
a sample space of 200 𝑥 106  gene disease pairings, 10  causal genes per disease and 
4000 druggable genes from the 20,000  in the genome. The dashed red circle encloses a 
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